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Preface 
 
The work presented in this thesis originates from the Oncology Clinic and the Institute 
for Cancer Research at the Norwegian Radiumhospital (now part of Oslo University 
Hospital). Clinicians and scientists form the multidisciplinary sarcoma group at the 
Norwegian Radiumhospital, which is closely integrated with the Scandinavian Sarcoma 
Group (SSG1). Founded in 1979, SSG established a network of sarcoma specialists in 
research, diagnostics and clinical care facilitating translational research in the Nordic 
countries. Wider collaborations have been established through intergroup-projects with 
the Italian sarcoma group (ISG2) and in an extensive European-American study group 
on osteosarcoma (EURAMOS3). When working with rare tumours needing highly 
specialized care, centralization to expert centres and international collaboration is 
mandatory for improving the prospects for our patients.  
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Abbreviations 
 
BAX Bcl-2-associated X protein 
BCD combination chemotherapy of bleomycin, cyclophosphamide and 
dactinomycin 
BCL2 B-cell CLL/lymphoma 2  
BS bone sarcoma 
CDK4 cyclin-dependent kinase 4 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CML chronic myelogenous leukaemia 
COSS Cooperative Osteosarcoma Study Group 
DDLS dedifferentiated liposarcoma 
EBV Ebstein Barr virus 
EFT Ewing family of tumours 
EGFR endothelial growth factor receptor 
EOI European Osteosarcoma Intergroup 
EORTC European Organisation for Research and Treatment of Cancer 
EURAMOS European American Osteosarcoma Study Group 
FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer 
GIST gastro intestinal stromal tumour 
IFI16 interferon, gamma-inducible protein 16 
IFITM1 interferon induced transmembrane protein 1 (9-27) 
IFN  interferon 
IL-15 interleukin 15 
IOR-OS2 Istituto ortopedico Rizzoli – osteosarcoma study 2 
IRF9 interferon-regulatory factor 9 
ISG Italian Sarcoma Group 
ISGSSG1 Italian-Scandinavian Osteosarcoma Study 1 
ISGSSG2 Italian-Scandinavian Osteosarcoma Study 2 
JAK Janus kinase 
KI Karolinska Institute 
KS Karolinska Hospital 
LS liposarcoma 
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MAP combination chemotherapy of methotrexate, doxorubicin and cisplatinum 
MDM2 Mdm2 p53 binding protein homolog (mouse) 
MDM4 Mdm4 p53 binding protein homolog (mouse)  
MPNET malign peripheral neuroectodermal tumour 
MTX Methotrexate 
NCI National Cancer Institute 
NF1 neurofibromin 1 
OAS oligo adenylate synthetase 
OS osteosarcoma 
p53 tumour protein p53 
PARP poly (ADP ribose) polymerase 
PEG polyethylene glycol 
RB1 retinoblastoma 1  
SS18 synovial sarcoma translocation, chromosome 18  
SSG Scandinavian Sarcoma Group 
SSGII SSG study II (1. Scandinavian osteosarcoma study) 
SSGVIII SSG study VIII (2. Scandinavian osteosarcoma study) 
SSX  synovial sarcoma, X breakpoint 1  
STAT signal transducer and activator of transcription 
STS soft tissue sarcoma 
TP53     tumour protein p53  
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labelling 
USP7 ubiquitin specific peptidase 7 (herpes virus-associated) (HAUSP) 
VIG combination chemotherapy of etoposide, ifosfamide and granulocyte 
growth factor 
WDLS well differentiated liposarcoma 
XAF1 X-linked inhibitor of apoptosis (XIAP) - associated factor 1 
 
 8 
List of papers 
 
Paper I:   Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, 
Stenwig AE, Willen H, Holmström T, Follerås G, Brosjö O, Kivioja 
A, Jonsson K, Monge O, Sæter G; 
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: 
prognostic factors for outcome and the role of replacement salvage 
chemotherapy for poor histological responders.  
Eur J Cancer 2003, 39; 488-494. 
 
Paper II:  Müller CR, Smeland S, Bauer H, Saeter G, Strander H:  
Interferon-α as the only adjuvant treatment in high grade 
osteosarcoma: Long term results of the Karolinska Hospital series.  
Acta Oncol 2005, 44; 475-480. 
 
Paper III: Müller CR, Namløs HM, Bjerner J,  Østensen IHG, Sæter G, Smeland S, 
Bruland Ø, Myklebost O: 
Characterization of Treatment Response to Interferon-α in 
Osteosarcoma Xenografts. 
Manuscript submitted march 2010  
 
Paper IV: Müller CR*, Paulsen EB*, Nordhuis P,  Pedeutour F, Sæter G, Myklebost 
O:   
Potential for treatment of liposarcomas with the MDM2 antagonist 
Nutlin-3A.   
Int J Oncology, 2007, 121; 199-205. 
  
                                                 
* contributed equally 
 9 
Introduction 
 
Sarcomas 
The mesoderm gives rise to bone, cartilage, muscle, endothelium and blood cells. Non-
haematological malignant tumours resembling these tissues are called sarcomas. The 
majority of sarcomas are thought to arise in pluripotent mesenchymal stem cells with 
the exception of a few neoplasms of probable neuroectodermal origin (Ewing family of 
tumours). Sarcomas are rare tumours with a stable incidence of 1% of all 
malignancies5, 6, but are relatively more common in childhood and adolescence where 
they constitute 6-7%7. Sarcomas are traditionally subdivided into two main groups, soft 
tissue sarcomas (STS) originating from soft tissues and bone sarcomas (BS) originating 
from bone or cartilage. 
 
Among over 50 subtypes of STS8, the four most common adult subtypes are 
pleomorphic undifferentiated sarcoma constituting 20-70% of STS, liposarcoma 10-
16%, fibrosarcoma <10-65% and leiomyosarcoma 5-10%. The ranges stated illustrate 
significant changes in the perception and definition of sarcoma histotypes over time and 
between pathologists9. Median age for STS as a group is 65 years8. The most common 
STS’ of childhood are rhabdomyosarcoma and fibrosarcoma7. 
 
Bone sarcomas are divided into osteosarcoma (OS), chondrosarcoma and Ewing's 
sarcoma, with a peak incidence in late childhood/adolescence for both OS and Ewing's 
sarcoma, as opposed to chondrosarcoma, which is essentially a tumour of adulthood10. 
 
The aetiology of sarcomas is poorly understood. Risk factors include chemicals 
(phenoxyacetic acids and chlorophenols used as herbicides11; dioxin12, 13 vinyl 
chloride14, 15, previous radiotherapy 16, 17, viral infections (human herpes virus 8 is the 
causative agent of Kaposi’s sarcoma)18, EBV in the development of smooth muscle 
tumours19 and acquired immunological defects. Some germ line mutations affecting 
tumour suppressor genes dispose for specific sarcomas (e.g. p53 in the Li Fraumeni 
syndrome20, Rb in retinoblastoma21, NF1  in neurofibromatosis related MPNET22 and c-
kit in GIST23).  
 
 10 
Sarcomas may originate at any anatomic site and the distribution varies greatly by 
histological subtype and within subtypes. Roughly half of STS are localized in the 
extremities24, and a similar distribution is found for bone sarcomas as a group. For OS 
approximately 90% are localized to the extremities25. 
 
Genetic alterations 
An estimated 15-20% of sarcomas harbour specific chromosomal translocations26 
(table 1). The resulting chimeric proteins are important for the biology of these tumours, 
commonly acting as abnormal transcription factors deregulating downstream genes in 
critical signalling pathways. The strong relationship between specific translocations and 
distinct sarcoma types indicate that they represent early and tumour-driving events in 
tumour genesis27, perhaps at the level of the suggested sarcoma stem cells. Fusions 
genes have become an important part of modern sarcoma diagnostics and variants of 
fusion genes may be associated with differences in outcome (e.g. in Ewing's sarcoma 
and synovial sarcoma28). The fusion gene products or their downstream signalling 
pathways may represent potential targets for treatment29.  
 
Table 1: characteristic fusion genes in sarcomas32 
tumour chromosomal aberration fusion gene 
alveolar rhabdomyosarcoma t(1;13)(p36;q14) PAX7–FOXO1 
 t(2;13)(q36;q14) PAX3–FOXO1 
alveolar soft part sarcoma  t(X;17)(p11;q25) ASPSCR1–TFE3 
angiomatoid fibrous histiocytoma  t(2;22)(q33;q12) EWSR1–CREB1 
clear cell sarcoma  t(12;22)(q13;q12) EWSR1–ATF1 
dermatofibrosarcoma protuberans  t(17;22)(q22;q13) COL1A1–PDGFB 
desmoplastic small round-cell tumour  t(11;22)(p13;q12) EWSR1–WT1 
endometrial stromal sarcoma  t(7;17)(p15;q11) JAZF1–SUZ12 
Ewing family of tumours t(11;22)(q24;q12) EWSR1–FLI1 
 ins(21;22)(q22;q12q12) EWSR1-ERG 
 t(16;21)(p11;q22) FUS-ERG 
fibromyxoid sarcoma t(7;16)(q34;p11) FUS–CREB3L2 
liposarcoma, myxoid  t(12;16)(q13;p11) FUS–DDIT3 
 t(12;22)(q13;p12) EWSR1–DDIT3 
synovial sarcoma  t(X;18)(p11;q11) SS18–SSX 
 
 
However, the majority of sarcomas have complex and variable genetic changes without 
balanced translocations. These sarcomas frequently have dysfunctional regulation of 
the cell cycle30, 31, either by inactivating mutational events in central regulators (e.g. 
TP53, CDKN2A or RB1), or increased copy numbers of antagonists (e.g. MDM2 or 
 11 
CDK4). These and other yet unknown factors contribute to the genetic instability in 
these tumours. 
 
Prognostic factors for sarcoma survival 
 
At present, the treatment approach to sarcomas is based on the malignancy grade, 
tumour type, resectablitity and the presence or absence of overt metastases. Other 
patient, tumour or treatment specific factors have been proven to be of prognostic 
importance, and may guide treatment decisions to some extent, and several of these 
factors are common to most sarcoma entities (table 2). 
 
Table 2: major factors with established beneficial impact on sarcoma outcome 
factor  STS OS EFT 
tumour low malignancy gradel yes yes n.a.** 
 non-metastatic yes yes yes 
 Extremity localization yes yes yes 
 small tumour volume yes yes yes 
treatment complete surgical resection yes yes yes 
 chemotherapy no* yes yes 
 radiotherapy yes no yes 
 initial treatment at expert centre yes yes*** yes*** 
 
yes: of proven importance; no: not of proven importance 
*exception for STS in children 
** not applicable, Ewing's family of tumours are always regarded of high malignancy grade 
*** low patient volumes make statistics uncertain, very few patients are treated outside paediatric oncology 
centres 
 
 
Malignancy grade: Malignancy grading is applied for the majority of STS and BS to 
improve the prediction of local aggressiveness and metastatic potential. The 
malignancy grade is usually based on the pathologist’s evaluation of intratumoural 
necrosis, mitotic rate and degree of cellular and architectural differentiation. The 
two most widely used systems are the FNCLCC33 and the NCI system34. However, 
the risk of metastasis varies within the group of tumours with high malignancy 
grade, and more recently prognostication systems have been developed by 
combining several tumour features. Engellau et al. proposed a stepwise model of 
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predicting risk of metastatic relapse for non-metastatic high grade STS defining two 
risk groups35. High risk tumours showed vascular invasion or at least two of three 
other features: tumour size >8cm, tumour necrosis and peripheral infiltrative growth 
pattern. The high risk group had a cumulative incidence of metastasis at five years 
of 51% compared to 5% for the low risk group. 
 
Histotype: Some sarcoma histotypes have a uniform behaviour and are thus 
independent of malignancy grading and prognostication systems. These include 
lipoma-like liposarcomas (relatively benign behaviour), myxoid round-cell 
liposarcomas (behaviour determined by the amount of round cells), dedifferentiated 
liposarcomas (highly malignant), synovial sarcoma (highly malignant), classical 
central OS (highly malignant), superficial (parosteal) OS (low malignancy) and EFT 
(highly malignant). 
 
Metastatic status: The presence of overt metastatic disease is the most important 
adverse predictor of outcome for soft tissue and bone sarcomas (table2). The site 
and number of metastases has further importance as isolated pulmonary 
metastases carry significantly better prognosis in both bone sarcoma36, 37 and 
STS38. This is due to the resectability of macroscopic disease, and underscores 
that chemotherapy is an ineffective substitute for complete surgical resection. 
 
Site and size: Extremity localization is a positive prognosticator due to the resectability 
of the tumour25. Bone sarcomas localized to the axial skeleton carry a grave 
prognosis25. Retroperitoneal liposarcomas present with larger tumour volumes and are 
more often resected with marginal or intralesional margins than appendicular 
liposarcomas39. 
Small tumour volume is independently and positively related to outcome in the both 
STS and bone sarcomas25, 35, 40. 
 
Demographic factors: Young age is a positive predictor of survival in STS38, 41, OS25 
and EFT42. Gender has been an inconsistent marker weakly favouring female sex 
and occasionally reaching statistical significance25, 42.  
 
Treatment related factors: Treatment at a sarcoma centre improves the outcome in 
STS and supposedly in bone sarcomas 43-46. Achieving a complete resection is of 
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central importance for the risk of relapse and survival for STS and bone sarcomas 
(table2)25, 41. The likelihood of chemotherapy response is not sufficiently predicted 
by the factors mentioned above. High dose regimes can improve tumour sensitivity 
to methotrexate in OS47, but a pre-treatment prediction of response to 
chemotherapeutic agents is not possible today. Recently described polymorphisms 
in folate metabolism modulating the response to methotrexate might prove useful48. 
Predictive impact of P-glycoprotein expression for chemotherapy resistance and 
survival has been shown in a prospective study but has so far not gained general 
acceptance or therapeutic impact49 50, 51. Preoperative chemotherapy in OS and 
Ewing sarcoma allows evaluation of the degree of residual viable tumour tissue at 
the time of the surgery, and this factor has been shown to be strongly predictive of 
long term outcome25, 42, 52; The hypothesis that it may be possible to improve the 
prospects for patients with initially poor tumour response is a central issue in the 
study forming the basis for paper 1. 
 
 
Treatment and outcome 
 
Treatment of the primary tumour: In both BS and STS, surgery is required to achieve 
local control of the primary tumour, and only in EFT may radiotherapy alone be 
successful in gaining local control53, 54. The importance of a complete resection of all 
identifiable tumour tissue has been demonstrated also for metastatic sarcoma55-57 
With high quality surgery in extremity localized OS a local relapse rate of only ~5% is 
reported in recent series25, 58, despite high rates of limb-salvage surgery.  In unselected 
series of STS of the extremity and the trunk wall, a local relapse rate of 15-27% is 
observed41, 59. The commonly contaminated resection margins in retroperitoneal 
sarcomas are the main cause for a local relapse rate of 59-68%60.  
Pre-operative radiotherapy may render some STS operable and post-operative 
radiotherapy can improve local control for STS subgroups and EFT with inadequate 
surgery61, 62.  
 
Systemic treatment for patients at high risk of developing metastatic disease: Most 
sarcomas of childhood and adolescence are viewed as systemic diseases at the time of 
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diagnosis, and may be cured by adjuvant chemotherapy. In OS, four drugs are most 
active and have become the basis of modern combination treatment: methotrexate63 , 
doxorubicin64, cisplatinum65 and Ifosfamide66, 67.  Pre-operative chemotherapy for bone 
sarcomas was introduced in the late 1970ies68, 69 to allow for the construction of custom 
made prostheses, and to attack probable micrometastatic disease as early as possible. 
However, the addition of pre-operative systemic treatment has not given any proven 
survival benefit70. Introduction of aggressive chemotherapy three decades ago has 
resulted in a considerable increase of 5-year overall survival for localized 
osteosarcoma, Ewing family of tumours and rhabdomyosarcoma from 10-25% to 60-
80%71-73.  
Although high-grade adult STS carry a significant risk of distant metastases, the use of 
adjuvant chemotherapy remains controversial. According to a recent meta-analysis 
adjuvant doxorubicin improves local and distant control rates by 6% at ten years, and 
an update of this meta analysis in 2007 showed a significant survival benefit of 6%74, 75. 
However, the EORTC 62931 study randomizing adjuvant doxorubicin and ifosfamide 
vs. observation alone has reported no improved progression free survival or overall 
survival76. Thus, there is no definitive proven benefit of adjuvant chemotherapy in the 
broad group of adult STS. However, studies have commonly lumped together tumours 
with varying risk profiles and chemosensitivity, possibly masking effects in more 
chemosensitive subgroups like synovial sarcoma and myxoid liposarcoma77. The 
challenge lies in the small patient subgroups limiting the possibility for targeted 
subgroup studies. 
For a mixed series of 1646 adult, resectable and nonmetastatic STS registered by the 
SSG, 5-year tumour related survival was over 70%43. Survival rates of  
retroperitoneal sarcoma are reported from 37-60%78 and vary by the histological 
subtype. One group found a 92% 5-year survival rate for well differentiated liposarcoma 
compared to 36% for dedifferentiated liposarcoma79. 
 
Survival rates  
Treatment of patients with overt metastases: A limited number of resectable metastases 
may be a curable situation in both OS and adult STS55, 57. Survival depends on whether 
a complete surgical remission can be achieved. 5-year overall survival for metastatic 
OS was reported with 29%; when a complete remission could be achieved, survival 
exceeded the 40% mark, whereas unresectable metastatic disease carried a very poor 
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prognosis with no survivors after 5 years57. Similarly for STS, patients selected for 
resectable pulmonary metastases achieved a 5-year overall survival of 38%55 whereas 
survival remains poor for most patients with a primary metastatic STS. A Chochrane 
meta analysis of chemotherapy in metastatic STS80 reports response rates to single 
agent doxorubicin ranging from 16-27% and median survival from 7.3  - 12.7 month with 
no additional benefit combining doxorubicin with additional agents. A combined analysis 
of 7 prospective EORTC studies including 2187 patients reported survival rates of 8% 
at 5 years and 5.6% at 8 years38, 54. The most significant predictor for long-term survival 
was response to chemotherapy and survivors were observed even in the patients with 
unfavourable prognosis as liver metastasis and high grade tumours. Dose escalation 
trials in adult STS have not been successful81, 82, and single agent doxorubicin remains 
the standard treatment for metastatic adult STS83, 84 with the notable exception of 
imatinib in GIST85.  
 
 
Current challenges in the treatment of sarcomas 
 
Control of the primary tumour is not the main challenge, as the constant development of 
advanced surgical techniques and the combination with radiotherapy for selected 
patients in general gives low rates of local recurrence when performed by expert 
centres. Some tumour localizations remain problematic due to limited surgical access, 
e.g. in the head and neck, spine, thorax, retroperitoneum and pelvis.  
The main challenge is to develop more efficient systemic treatment for patients with 
overt metastatic disease or for patients at high risk for developing such metastases. 
In OS and EFT, where chemotherapy has improved outcome significantly, the 
challenge remains to increase event-free survival beyond 60-70% for patients with 
localized disease and beyond 10-30% for patients with initial metastases. To increase 
survival for poor histological responders after neo-adjuvant treatment is also imperative, 
as is the reduction of the current formidable toxicity. 
For the heterogeneous group of STS the main challenges are to more accurately 
identify the patients at high risk of developing metastatic disease, to develop more 
effective systemic treatment and to adapt treatment to the tumour biology of the 
individual subgroups. In the majority of STS's the efficacy of existing systemic treatment 
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is poor; the role of adjuvant chemotherapy remains disputed and combination regimes 
have not clearly surpassed single agent doxorubicin as the standard of care. 
 
Much progress has been made to elucidate the biological basis for some subtypes of 
sarcomas, and for a few of these, treatment success has been achieved by targeting 
key signalling pathways. This approach appears to be the most promising for all 
sarcomas. However, the low incidence, tumour heterogeneity and need for an expert 
multidisciplinary approach increase the challenges related to improving treatment 
results, and both centralization of patients to expert centres and large multicenter 
collaborations are important for further improvement. In fact it may be argued that a 
significant potential in improving particularly adult STS outcome remains unrealized by 
treating many patients at local hospitals without the necessary expertise. The effect of 
securing correct referral to expert centres without prior surgery for all patients may 
outweigh any novel research impact, at least in the short term.  
  
New drug candidates investigated at The Norwegian Radium 
Hospital. 
Our group has developed a specific interest in the possible role of interferon and mdm2 
inhibitors. Interferon has the advantage of being a developed and well known drug for 
other conditions (table 3), and some data have suggested that interferon has activity in 
OS (paper 2). As for mdm2, our group’s long standing interest in the 12q13-14 
amplicon86 was the background for our collaborative work  with L. Vassilev87 on 
preclinical studies of mdm2 amplified sarcoma cell lines. 
 
Before discussing the actual work performed in this study a short general background 
will be given for these two new candidate approaches in sarcoma treatment.  
 
Interferon 
Five decades after their discovery, interferons (IFNs) have clearly defined indications in 
virology, neurology and oncology (table 3), but many important questions remain 
unanswered. The only sarcoma evidently sensitive to IFN is Kaposi’s sarcoma88, 
whereas a possible role in the treatment of Osteosarcomas is under investigation. 
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Table 3: clinical applications of type I interferons89 
indication  
non-malignant chronic viral hepatitis 
 papillomatosis and condylomata acuminta 
 haemangioma of infancy 
 multiple sclerosis 
malignant AIDS-related Kaposi’s sarcoma 
 chronic myeloid leukaemia 
 myelomatosis 
 hairy cell leukaemia 
 essential thrombocytopenia 
 carcinoid tumours 
 malignant melanoma 
 renal cell carcinoma 
 
Originally grouped according to the secreting cell type, IFNs are now classified into type 
I, II and III according to receptor specificity and sequence homology. The nine distinct 
type I IFNs bind to a common heterodimeric receptor. IFN-  (previously termed 
leukocyte IFN) consist of13 different subtypes whereas IFN- , (previously fibroblast 
IFN) and  other type I IFNs exist only in one form90. 
 
Antitumour activity of type I ( ) IFNs was demonstrated in the late 1960ies. These 
effects can be separated into host dependent mechanisms (innate and adaptive 
immunity, angiostatic effect) and intrinsic tumour suppressor activity (mediated by 
expression of  interferon stimulated genes)91. 
 
Immune-mediated effects: IFNs exert a broad range of immunoregulatory effects and 
promote immune functions. For example, type 1 IFNs activate dendritic cells, increase 
the cytolytic activity of macrophages and NK cells, induce the production of IL-15, prime 
T-cells and increase survival of T-cells leading to tumour cell kill, although the relative 
physiological relevance of these functions remains unclear92. Endogenous IFNs play a 
constitutive role in restricting emergence and development of tumours91, 93. Recently, 
both type 1 and 2 IFNs have been shown to be involved in the interactions between 
tumour and the immune system (immunoediting92). 
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Angiostatic effects: IFN was the first recognized angiostatic agent with clinical 
efficacy in angioproliferative tumours like Kaposi’s sarcoma and life threatening 
haemangioma of infancy88, 94. This angiostatic effect is not related to the 
antiproliferative effects of interferons95 and dependent on frequent administration of 
an optimal biological dose and not the maximal tolerated dose in a bladder cancer 
model96. 
 
Intrinsic tumour suppressor activity: IFNs exert direct tumour suppressor activity 
although the detailed mechanism is not yet known. Interaction with the p53 pathway 
has been demonstrated97. IFNs can halt cell cycle progression and this process is 
paralleled by OAS increase, inhibition of proto-oncogene expression and it may be 
related to cell differentiation98. IFN- -mediated apoptosis in malignant cells is 
largely dependent on the activation of different caspases, and is also associated 
with the disruption of mitochondrial integrity and release of cytochrome c99. Recent 
genome wide profiling efforts have established several hundreds of IFN stimulated 
genes with largely undefined importance for the treatment response100-102.  
 
 
MDM2 antagonists  
 
The tumour suppressor protein p53, kept at very low levels in unstressed cells, is rapidly 
stabilized and activated in response to environmental and intracellular stress. p53 
exerts its antitumour effects primarily by transcriptional activation leading to induction of 
cell cycle arrest, DNA repair, apoptosis or senescence103 . In addition to transcriptional 
activation and probably less important, p53 exerts transcription independent pro-
apoptotic function by BAX mediated stabilization of the mitochondrial membrane104.  
 
p53 and MDM2 form an auto-regulatory feedback loop by which the two proteins 
mutually control each other's function. Targeting the MDM2 gene promoter.p53 
increases cellular MDM2 levels. MDM2 inactivates p53 by blocking its transactivation 
domain105, promotes nuclear export of p53106 and p53 degradation107. Cellular stress 
signals release p53 from MDM2, a process thought to be mediated by specific 
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phosphorylation of both proteins108. More recent data indicate that MDM2 levels are 
critical for p53 control and that destabilisation of MDM2 is an important factor for 
initiating a p53 response109.  
 
Approximately half of all malignancies including sarcomas carry a deletion or 
inactivating point mutation of TP53, and a significant proportion of malignancies with wt 
TP53 have defects in the signalling network making the p53 response dysfunctional110. 
In OS, 22-39% have been found to have p53 mutations111, 112; a further 16% of OS and 
29% of liposarcomas deactivate p53  by an MDM2 amplification113. MDM2 protein 
overexpression in the absence of gene amplification has been observed113. 
Investigating the MDM2 gene variant SNP309, even a modest 2-4 fold overexpression 
of MDM2 could be shown to promote cancer development114.   
 
Treatment rationale: as tumours with MDM2 gene amplification almost exclusively 
retain wild-type TP53 but loose p53 tumour suppressive function116, 117, inhibiting MDM2 
might reactivate p53 in cancer cells. Recently, the first potent and selective small-
molecule MDM2 antagonists, the nutlins, were identified from a class of cis-imidazoline 
compounds. Nutlins bind to the p53 pocket of MDM2 and inhibit the p53–MDM2 
interaction with a high degree of specificity. In vivo treatment with Nutlin 3a was well 
tolerated in several xenografts models. Proliferating cancer cells retaining wild type p53 
were effectively blocked in G1 and G2 phases, and underwent apoptosis when 
exposed to low micromolar concentrations of nutlins87. No anti tumour effect was 
observed in cells carrying a mutant or deleted p53 indicating that an intact p53 pathway 
is necessary for this effect.  
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Aims of the present study 
During the last decades multidisciplinary efforts have changed the prospects for 
many sarcoma patients considerably. Further improvements in the treatment of 
these rare tumours will depend on conquering the challenge of inherent and 
acquired chemotherapy resistance, in particular in patients with inoperable or overt 
metastatic disease.  
 
The effect of systemic treatment may be improved by at least three general 
strategies:  
1.  Optimization of the administration of established agents and combination 
regimens 
2.  Further research into identified promising agents which appear to have effect 
in sarcoma, but where current evidence is insufficient. Aims should be both 
to demonstrate clear clinical efficacy and to increase the knowledge of 
mechanisms of action. 
3.  Development of entirely new drugs which may be efficacious alone or in 
combination with known agents. Currently the most promising approach is 
targeting the signalling networks of sarcoma cells and their 
microenvironment.  
 
This thesis is based on projects illustrating each of these three strategic 
approaches, with the following aims: 
1. To examine the effect of increased chemotherapy aggressiveness in 
osteosarcoma, and to use replacement salvage chemotherapy to increase 
survival in patients with poor histological tumour response to pre-operative 
treatment 
2.  To further assess interferon as an agent in osteosarcoma by 
 -  Analysing long-term effects after adjuvant treatment with single agent 
interferon in a clinical series and 
 -  Investigating its antitumour effect and effects on signalling in a xenograft model 
3. To study the effects of a new compound, the small molecular MDM2 
antagonist Nutlin, in soft tissue sarcoma cell lines selected for amplification 
of the MDM2 gene. 
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Summary of publications 
 
Paper I:   
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors 
for outcome and the role of replacement salvage chemotherapy for poor 
histological responders. 
 
SSG VIII applied a combination of the current most effective drugs for the treatment of 
osteosarcoma. The results with relapse-free and overall survival of 63% and 74% at 5 
years represent an apparent improvement over the less intense preceding SSG II 
regimen, and the results are comparable to the best published series.  The salvage 
chemotherapy approach with etoposide and ifosfamide failed to improve results for poor 
histological responders, as continued exposure to the conventional agents doxorubicin, 
cisplatinum and methotrexate appeared at least as effective as switching to a dose-
intense regimen with the new drugs.  
Unexpectedly, the data showed an independent gender specific survival advantage for 
female patients which remains unexplained. 
 
 
Paper II: 
Interferon-α as the only adjuvant treatment in high grade osteosarcoma: Long 
term results of the Karolinska Hospital series. 
 
The Karolinska series represents a unique treatment approach for nonmetastatic high-
grade osteosarcoma with primary resection followed by single agent (semi-purified, 
leukocyte) interferon- . This consecutive series was started before the introduction of 
aggressive combination chemotherapy in 1971 and continued through 1990, enrolling 
89 patients. The toxicity was limited and comparable to other series using long-term 
adjuvant IFN. The observed 10-year metastases-free and sarcoma specific survival 
rates were 39% and 43%, respectively. The apparently improved outcome as 
compared to historical controls could not be explained by second line 
chemotherapy at relapse, as only one of seven survivors after relapse received 
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chemotherapy. These observations suggest activity of interferon-  as adjuvant 
treatment in high-grade osteosarcoma. 
 
 
Paper III: 
Characterization of Treatment Response to Interferon  in Osteosarcoma 
Xenografts 
 
We screened five osteosarcoma xenografts for specific growth delay to IFN-  and 
explored molecular mechanisms involved in response and resistance by analyzing the 
transcriptional response. Only one of five xenografts displayed growth inhibition and this 
was compared to two resistant xenografts. A common set of 79 genes was identified in 
response to IFN-treatment independent of the growth inhibiting effect, and the majority 
represented well characterized interferon stimulated genes. The expression of 121 
unique genes changed only in the IFN-sensitive xenograft, and subsets of these genes 
are involved in cell adhesion and osteogenic tissue development. Combination 
treatment with interferon and doxorubicin showed improved growth control rates. 
 
  
Paper IV: 
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A 
 
We examined the response to Nutlin-3a in a panel of five osteosarcoma and four 
liposarcoma cell lines. Wild type p53 cell lines displayed a dose dependent inhibition of 
cell proliferation when treated with increasing concentrations of Nutlin 3A. In cells with 
MDM2 amplification, Nutlin efficiently stabilized p53 and induced downstream p53 
dependent transcription and apoptosis. An antiproliferative effect of Nutlin was also 
observed in cell lines with wt TP53 but without amplified MDM2, but apoptosis was 
not induced. Inhibiting the MDM2-p53 interaction in these cell lines reactivates an 
otherwise intact p53 pathway. 
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Results and Discussion: 
 
 
Can outcome in OS be improved by further refinement of current 
treatment approaches?  
 
To improve on the results from SSG II52 two assumptions were made in the 
planning of SSG VIII. The first was that more aggressive pre-operative treatment 
would improve both histological response and survival. Thus pre-operative 
treatment was intensified by increasing the methotrexate dose and by adding 
doxorubicin and cisplatinum. In the postoperative phase supposedly less effective 
drugs (dactinomycin, bleomycin, and vincristine) were omitted to allow for 
continuation of the pre-operative agents at adequate dose intensity (in good 
responders). The second assumption was that in poor histological responders, 
postoperative replacement chemotherapy with other agents (etoposide and 
ifosfamide) would improve outcome. The rationale for this was that the persistence 
of viable primary tumour tissue indicated chemoresistance also at the 
micrometastatic level, and that the switch to an ifosfamide/etoposide combination 
could circumvent this resistance. Ifosfamide had shown considerable activity in 
second line OS treatment66, 67, and there was already a positive Italian experience 
with ifosfamide/etoposide in poor histological responders72.  
 
SSGVIII was successful in increasing both histological response and survival as 
compared to the preceding SSG II, and the results were comparable to those of the 
best contemporary studies72, 115, 116. However, the gap in outcome between good 
and poor histological responders remained.  
 
Histological response to pre-operative chemotherapy is recognized to be one of the 
most important predictors of outcome in high-grade OS, and several trials apart 
from SSGVIII have tried to adjust the post-operative treatment in poor responders 
to improve results. Poor response to preoperative methotrexate/BCD could not be 
compensated by postoperative addition of doxorubicin and cisplatinum117, 52, 118, 119. 
To our knowledge only one study72 has been able to close the survival gap between 
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poor and good responders, and that was by continuing the same drugs 
postoperatively and add ifosfamide and etoposide in the poor responders. Our later 
SSG VIII study, where the same drugs were introduced but replaced the pre-
operative drugs did not succeed. It should be underlined that even in poor 
responders survival is clearly increased over patients treated by surgery alone 
(from ~20% to ~55%). Poor histological response does thus not indicate total 
chemoresistance at the micrometastatic level, only somewhat decreased sensitivity. 
This is supported by the observation in the relatively large group of grade II 
responders, who where treated differently in two separate phases of the SSG VIII 
study. Patients who were switched to etoposide/ifosfamide (VIG) actually had a 
trend towards poorer metastasis-free survival than those continuing methotrexate, 
doxorubicin and cisplatinum (MAP). Therefore, the collective data from SSG VIII 
and IOR-OS2 indicate that adding etoposide/ifosfamide to MAP is superior to 
replacing MAP with the same agents. 
It could be argued that the intermediate dose of ifosfamide applied in SSGVIII 
(4,5g/m2) was insufficient to overcome chemoresistance in the salvage arm. In 
retrospect a higher ifosfamide dose would appear feasible when considering the 
relatively low rate of grade 4 haematological toxicity after VIG. 
SSGVIII supports that modern chemotherapy for OS should start with a three drug 
combination of methotrexate, doxorubicin and cisplatinum (MAP), and that these 
drugs should be continued postoperatively regardless of histological response. Our 
data support that adding ifosfamide and etoposide to postoperative MAP in poor 
responders is a better strategy than replacing MAP, and the effect of this strategy is 
currently being tested in the EURAMOS1 study.  
 
The Cox regressional analysis identified low tumour volume, high serum 
methotrexate at 24h and female gender as independent predictors of improved 
metastasis-free survival. Histological response was a significant factor at the 
univariate level (p=0,03), but fell short of significance in the multivariate analysis. 
This may be due to the relatively small size of this study (113 patients). However, 
the increase in the fraction of good responders compared to the T10-based SSGII 
was not reflected by a comparable survival benefit. In their last randomized study, 
the EOI found that increased dose intensity correlated to the degree of necrosis but 
not survival indicating that necrosis is likely to be a protocol dependant variable, 
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and that its relative importance as predictor of survival decreases with increasing 
treatment intensity120. 
The strong predictive power of female gender in the Scandinavian OS population is 
unique in the literature, and so far remains unexplained. This effect of gender was 
not seen in historical controls treated by surgery alone121, and indicates that one 
explanation could be differences in the effect of chemotherapy, e.g. through 
differences in drug sensitivity, pharmacokinetics and/or drug metabolism. However, 
there was no indication of gender-specific differences in serum methotrexate levels 
in SSG VIII or SSG II. Interestingly, a positive prognostic impact of female gender 
was also found in the KS IFN experience (paper 2), and related to a difference in 
drug efficacy, the combined data indicate that this would be true for both IFN and 
combination chemotherapy. 
 
Earlier reports suggest that increased dose and dose intensity, in particular of 
doxorubicin and methotrexate, are associated with a better outcome47. Several 
groups including SSG have found correlations between high serum levels of 
methotrexate and improved histological response and survival52. SSG VIII supports 
these findings and found a serum methotrexate level >4,5 µM at 24h to be an 
independent predictor of improved metastasis-free survival, and in the subsequent 
ISGSSG1 study methotrexate doses were modified per patient and per course to 
achieve a pre-set target for serum methotrexate.  
However, the data regarding the importance of chemotherapy intensity are not 
consistent, and a large retrospective analysis from the German cooperative 
osteosarcoma group could not prove that higher then average dose intensity of 
conventional chemotherapy correlated with better outcome122. Prospective studies 
have examined different strategies of further dose intensification. The ISGSSG1 
trial attempted to "maximize" chemotherapy by combining ifosfamide 15 g/m2 with 
cisplatinum, doxorubicin, methotrexate and mandatory granulocyte colony 
stimulating factor support. Furthermore methotrexate treatment was optimized by 
modifying dose according to serum  methotrexate measurements. Toxicity was 
increased but survival was similar to SSGVIII123.  
The concept of increasing the dose intensity by compressing the treatment interval 
(dose-dense chemotherapy) was tested by the last EOI randomized study. A dose 
dense schedule of the two drug regime of doxorubicin and cisplatinum was 
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compared to conventional intervals and did not show a survival benefit120. Dose 
escalation with peripheral blood stem cell support in primary metastatic or 
inoperable OS was addressed by the ISGSSG2 study. The toxicity was 
manageable but survival rates were discouraging124. Another trial following a similar 
strategy in bone sarcomas with unfavourable prognosis failed to show survival 
benefits and reported intolerable toxicity125. Similarly, high dose chemotherapy with 
stem cell support has not been shown to be superior to conventional relapse 
therapy in relapsed patients126, 127. 
 
Collectively the data show that osteosarcoma survival has improved during the last 
three decades through gradual identification of the most active agents, and to some 
degree by intensification of their combined use. However, further intensification 
beyond the current standards for methotrexate, cisplatinum, doxorubicin and 
ifosfamide is probably not the way for further improvement. Current short and long 
term toxicity is significant and needs to be reduced128 . Future strategies should 
focus on better individualized and risk-adapted treatment with the development of 
robust pre-treatment markers for the individual patient. These may include 
individual pharmacokinetic factors. Whereas a general increase in dose intensity 
was not successful, an individualized dose adjustment based on drug serum levels 
may be pertinent for more drugs than methotrexate. However, the need for the 
development of new effective drugs with low toxicity is apparent. 
 
Finally, SSG VIII represents a relatively small phase II study with all consequent 
limitations that are attached to the interpretation of its data. In order to properly 
address the future challenges for all rare tumours including OS, intergroup 
collaborations allowing proper randomized trial designs are essential. 
 
 
Single agent IFN-  as adjuvant treatment in OS  
 
During a twenty year period, patients with resectable non-metastatic osteosarcoma 
were offered adjuvant IFN at the Karolinska Hospital (KS) in Stockholm129, 130 .  The 
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series was initiated in 1971 before the international introduction of effective 
chemotherapy, in part based on the assumption that OS might be induced by an 
oncogenic virus. An early indication of an effect on relapse-free survival led to the 
continuation of this project129. Furthermore, evolving preclinical data from the Karolinska 
Institute (KI)131, 132 and other institutions133-135 confirming the antitumour effect of IFN-
in vitro and in vivo combined with limited toxicity136, 137 was thought to strengthen the 
rationale for IFN use despite the internationally evolving combination chemotherapy. 
When a positive effect of IFN was indicated, the diagnosis of high grade OS in the first 
28 patients was subjected to a confirmatory independent review in 1976129. Additional 
support for diagnostic accuracy in the IFN series is provided by the close cooperation 
between sarcoma pathologists within SSG, with regular slide reviews and a low rate of 
misclassification in later studies where KS has participated (SSGVIII, ISGSSG 1).  
 
The 89 patients given adjuvant IFN represent a consecutive series from 1971 to 1990. 
The distribution of primary tumour sites, age and gender is comparable to other 
reports25, 138, but only 9/102  patients admitted to KS were diagnosed as having 
detectable metastases at diagnosis. This fraction was lower than in other reports (12-
20%)25, 139, and may represent an under-diagnosis of pulmonary metastases in the KS 
series. A small decline in the number of IFN-treated patients in the last years is probably 
explained by a remapping of the health care regions leaving the Karolinska Hospital a 
smaller geographical catchment area.  
 
The analysis of potential prognostic factors showed that in this limited patient material 
large tumour diameter, male sex and intralesional surgical margins were predictors of 
inferior survival. The first two factors were also reported for Scandinavian patients 
treated with chemotherapy (see discussion of paper 1). Inadequate margins are closely 
associated with the risk of local recurrence in OS25, and the relatively high rate of 
intralesional surgery in this series (11%) resulted in a high rate of local recurrence 
(22%) and a 2,4-fold increased risk of sarcoma specific death. This may be related to 
the absence of pre-operative chemotherapy in parallel with a relatively high level of 
ambition as regards limb salvage surgery (42%).  
 
A small and retrospectively collected group of patients treated in the early seventies by 
surgery alone at other Swedish centres had a slightly better survival than a historical 
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control group at the KI140. These groups were both of small size and it is important to 
note that survival in the KI control group (17% after 2.5 years) is comparable to both 
Scandinavian121 and international reports141, 142. Thus there is no evidence of a change 
in the natural history of OS which can explain the improved survival in the INF-treated 
patients143.  
 
This long term follow-up study of the IFN-treated OS patients from KS shows that the 
percentage of survivors at 10 years (43%) is considerably higher than for historical 
controls treated by surgery alone (11-18%)121, 140-142, but still appears lower then for 
modern combination chemotherapy (55-75%)25, 72, 120. The data allow no conclusion as 
to whether the IFN dose increase in the late series was more efficacious. The survival 
increase found can not be assigned to second line chemotherapy as the majority of 
survivors remain in their first remission, and only one of the long-term survivors has 
received chemotherapy at relapse. 
 
An effect from adjuvant IFN is thus clearly suggested by this experience from KS. 
However, it should be emphasised that the data in the KS series are derived from a consecutive 
patient series rather than a formal clinical study, and that the results therefore must be 
interpreted with considerable caution. It should also be kept in mind that there are, to our 
knowledge, no reports indicating that IFN has effect in metastatic disease, which has 
traditionally been a pre-requisite for adjuvant treatment. Unpublished experiences from 
KS and the Rizzoli Institute (Hans Strander and Stefano Ferrari, personal 
communications) indicate that there is no effect of IFN on established metastatic 
disease. 
 
Thus the effect of IFN in OS remains unclear and should to be put to the test in a well 
designed randomized controlled trial in combination with chemotherapy. This was 
attempted in the COSS 80 study where patients were randomized to receive IFN-β or 
not as maintenance treatment after completing chemotherapy118 – no effect was seen. 
However, this trial used a low IFN dose for a short period of time. For the subgroup of 
good responders to preoperative chemotherapy the addition of maintenance IFN is 
currently being tested in EURAMOS-1. The question whether poor responders would 
benefit from IFN maintenance treatment is not addressed in that trial. 
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Antitumour effects of interferon in experimental models  
 
In OS and other malignancies, resistance to IFN-  is common but poorly 
understood. A better understanding of the molecular mechanisms of response and 
resistance is required to effectively utilize this agent. Furthermore, biomarkers are 
required to select treatment options and may help to define new cellular targets. 
 
Human OS xenografts in immuno-incompetent mice have been widely used as 
disease models144. Subcutaneous xenografts offer certain advantages in the study 
of OS. They are relatively easy to establish, make it possible to transplant human 
tumour samples without the prior selection process in cell culture, and have been 
shown to be relatively stable genetically over long passage times145, 146, giving 
abundant access to fresh tumour tissue. Importantly, they give the opportunity to 
perform repetitive therapeutic experiments. These models have been shown to be 
important for the preclinical assessment of treatment response144. In our research 
group, OS xenografts have been used to profile the response to doxorubicin, 
cisplatinum, ifosfamide and methotrexate147, 148 and to experimental agents. 
Disadvantages of this model include a necessary selection of aggressive tumours 
for growth to occur, and a low inherent tendency for metastasis, probably due to the 
rapid growth of the primary implant not leaving time for detectable metastases to 
develop. Furthermore, the immune deficiency of the host and the species specific 
action of IFN limit this model to the study of direct antitumour effects of human 
relevance. However, as regards the analysis of signalling and molecular effects 
secondary to IFN within the cancer cells, the model may be highly relevant.   
 
Pegylation prolongs IFN half life and is expected to augment and prolong IFN 
signalling149. The unexpected low response rate in the reported xenograft panel (paper 
3) when compared to an older series131 and the short-lived effect on expression profiles, 
prompted us to examine response to  unpegylated IFN, but our xenografts appeared 
equally resistant. Interestingly, a high daily dose of unpegylated IFN was able to induce 
complete remission in one IFN-sensitive xenograft.  Examination of the elimination rate 
of PEG-IFN by radioiodine-labelling indicated a shorter half life than expected, and 
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shortening the dose interval improved the response to PEG-IFN in the sensitive 
xenograft. Others have shown that recombinant IFN-  was less effective than natural 
IFN-  in an OS-xenograft model150 and that IFN-  subtypes have different efficacy in 
several other model systems151. The diversity of type I IFNs is further highlighted by 
superior efficacy of IFN- over IFN  in some cell lines152. Our findings may indicate 
that recombinant IFN 2b is not the optimal IFN for the treatment of OS, although there 
may be indirect effects through host stroma and immune system not detected in the 
xenogeneic models92, 153.  
 
To explain the low response rate it may be relevant that three of our tumours (including 
the sensitive one) were exposed to chemotherapy before xenografting, whereas all the 
Karolinska tumours were chemotherapy naïve. The sensitive xenograft being the only 
one of metastatic origin is interesting taking into account the disappointing clinical 
experience with IFN in overt metastatic osteosarcoma. Furthermore, our xenograft lines 
were maintained over a longer time before the experiments. Although passage number 
did not impact on response to chemotherapy in a previous study on these xenografts148, 
we can not exclude that primary IFN resistance may be caused genetic or epigenetic 
alterations over time. However, interferon sensitivity was documented in all together 
three passages of the same xenograft. Finally, there were no apparent differences in 
the xenografting method between our and the Swedish xenograft series. Based on only 
one sensitive xenograft, no firm conclusions can be drawn and findings have to be 
viewed as preliminary. 
 
For the sensitive xenograft, global transcription profiling did not indicate selective 
impact on cell cycle regulators or cell death genes at the mRNA level. Genes 
reported by others, e.g. IFITM1 (9-27)101, 154 and IFI16101  were expressed in all 
three cell lines without apparent relation to response. We describe IFN-induced 
changes in cellular adhesion genes and genes involved in differentiation and 
suggest that these pathways may be involved in the IFN response in this particular 
xenograft. Again, these findings have to be viewed with caution as they are based 
on one xenograft only, and because the fold changes are relatively low. However, 
IFN-a was shown to induce differentiation in an OS model155  and  increased 
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differentiation capacity in CML cells156, and this mechanism may correlate or 
perhaps contribute to a reduced proliferation rate. 
 
The global transcriptional response demonstrated activation of central IFN 
stimulated genes in all three xenografts independent of a growth inhibitory effect. 
The activation of genes related to the innate antiviral immune response and of the 
adaptive cellular immune response was not correlated with the growth inhibitory 
effect of IFN in our model system.  
 
Resistance to IFN has been linked to defects in signal transduction. Others have 
described resistance due to circulating IFN receptors157, suppressed expression of 
JAK158 or STAT2159, or methylation of the proapoptotic genes (XAF1)152. In our 
model, transactivation of IFN-stimulated genes with ISRE in promoters indicate an 
intact signal transduction. The observation is supported by the expression of two 
genes involved in the classical JAK STAT signal transduction cascade, STAT1 and 
IRF9. The activation of the proapoptotic genes Trial and XAF1 makes at least a 
broad demethylation of their promoter regions of IFN stimulated genes unlikely. 
Selective demethylation, post-transcriptional silencing by miRNA or selective 
destruction by targeting for ubiquitinilation remain untested in our model.  
 
An interesting observation was done in pilot experiments combining IFN and 
doxorubicin. The combination appeared to have at least additive effects. Doxorubicin 
has been shown to induce cell death genes in the treatment of hepatocellular 
carcinoma160, but we could not show a clear induction of these genes by doxorubicin 
after 24h in one xenograft. A number of potential predictors of responsiveness to 
doxorubicin have been described in our OS xenograft system147 but were not confirmed 
in our study.  
 
Once confirmed, these finding supports a strategy to combine IFN with other agents. 
IFN has been shown to kill multidrug resistant OS cell lines161 and synergy with other 
agents has been shown in the treatment of non-Hodgkin lymphoma162 and recently in 
the treatment of renal cell carcinoma163. The sensitisation of p53 by IFN97 would be 
expected to make tumours with intact TP53 more prone to many types of 
chemotherapy. The notion is also supported by induction of a broad IFN response on 
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the molecular level even in our resistant xenografts. Finally, IFN was shown to mobilise 
stem cells in leukaemia rendering this tumour responsive to cytotoxic chemotherapy164. 
It remains to be shown whether this effect can be exploited in solid tumours.  
 
 
Effect of mdm2 inhibition in OS and LS  
 
The in silico development of a class of small protein antagonists of MDM2, the Nutlins, 
represented a major breakthrough in molecular biochemistry87. Targeting the MDM2-
p53 regulatory circuit is expected to reactivate the p53 pathway in a large range of 
tumours. At the start of this work it had already been shown that Nutlin was effective in 
a single osteosarcoma in vitro cell line with MDM2 amplification both when grown in 
vitro and in vivo. We wanted to explore the therapeutic potential of this drug in both 
osteosarcoma and liposarcomas depending on their status of TP53 mutation and 
MDM2 amplification. An initial collaboration165 showed for the first time efficacy in a 
xenograft established directly from a patient’s osteosarcoma. 
 
In paper 4, we showed that Nutlin-3a had a dose dependent anti-proliferative effect in 
wild type TP53 osteo- and liposarcoma cells. The p53 protein was stabilized and its 
level thus increased. In MDM2 amplified cell lines, we observed a Nutlin-induced 
transactivation of p53 targets MDM2, CDKN1 (encoding p21) and BAX, and down 
regulation of BCL2. Consistent with activation of p53 function, analysis of the cell cycle 
profile confirmed the activation of both G1 and G2 checkpoints. TUNEL labelling, 
Caspase 3 activation and PARP cleavage confirmed p53 dependent induction of 
apoptosis as the mechanism of cell death. Nutlin at the maximal tested dose did not 
arrest the growth of control cell lines harbouring a TP53 mutation. Wild type TP53 cell-
lines without MDM2 amplification responded only with cell cycle arrest but not 
apoptosis. 
 
These findings confirm that MDM2 amplified liposarcomas and osteosarcomas 
contain an otherwise intact p53 pathway. A similar observation was recently made 
in synovial sarcoma cell lines where the fusion-protein SS18-SSX stabilizes 
MDM2166. Resistance to genotoxic stress by the topoisomerase II inhibitors 
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doxorubicin and etoposide is common in both liposarcoma and synovial sarcoma 
and it was shown that topoisomerase inhibitors did not disrupt the MDM2-p53 
interaction and that p53 remained transcriptionally inactive. In these sarcomas, 
MDM2 antagonism targets the driving defect in the cancer genome and, in a 
parallel to inhibiting constitutively active tyrosine kinases in CML167 and GIST85, 
carries the promise of significant clinical efficacy.  
 
Tumours with wild type p53 and normal or low level amplification of MDM2, as 
exemplified by the cell line U2OS, may also respond to MDM2 antagonists, 
although only with cell cycle arrest and not with apoptosis. This differential 
response may be caused by different affinity of p53 to the promoters of cell cycle 
regulators compared to proapoptotic genes, or may be explained by the 
complementary roles of the homologues MDM2 and MDM4 in regulating p53. It has 
been shown that loss of MDM2 mainly stabilized p53 levels whereas loss of MDM4 
function increased p53 transactivational activity168. Whereas the MDM4 protein 
could be detected in U2OS, it is undetectable in cells with high level amplifications 
of MDM2, possibly because of MDM2 mediated degradation of MDM4169. Nutlin 
selectively blocks MDM2 but not MDM4170. The blocked apoptotic p53 response 
could be rescued by cellular stress signals that phosphorylated MDM4 dissociating 
the MDM4 complex with the deubiquitinylating enzyme USP7 (HAUSP) leading to 
reduced cellular MDM4 levels171. This mechanism could explain the synergistic 
effect of the selective MDM2 antagonist Nutlin and genotoxic agents in some 
cases172 (Ohnstad et al., unpublished). Alternatively, another as yet undetected 
aberration in the p53 pathway could explain the differential block of p53 apoptotic 
functions. 
 
The adverse effects of unspecific genotoxic agents, particularly induction of genetic 
instability and secondary malignancies are irreversible and often difficult to manage. 
With an increasing awareness of the quality of life of sarcoma survivors128, 
nongenotoxic activation of the p53 pathway would therefore be an attractive therapeutic 
strategy for cancers with intact p53-dependent signalling173. Trials with small molecular 
antagonists of MDM2 have now been initiated 174. 
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Conclusions and perspectives 
The present work has attempted to address different approaches to improve the 
systemic treatment in high-grade sarcoma, based on the three general strategies 
outlined on p. 21: 
 
1a. Improve chemotherapy with established agents (combine more agents and 
increase dose levels). 
This approach has been beneficial for childhood STS, but has been less effective in 
adult STS were single agent doxorubicin remains the standard of care84. In OS 
some intensification has been beneficial, as illustrated by the apparently improved 
results in SSG VIII when compared to SSG II. However, subsequent studies as 
exemplified by ISGSSG1 showed that further intensification added considerable 
toxicity without further improvement in tumour-related outcome123. Similar data have 
been reported for the Ewing family of tumours175. Thus further dose intensification is 
probably not the right strategy for further improvement in survival. 
 
1b. Switch to replacement salvage chemotherapy in poor responders to pre-
operative chemotherapy in osteosarcoma. 
Poor response to chemotherapy remains an important treatment related prognostic 
factor for survival. With one possible exception72, salvage strategies have not been 
able to compensate for an initial poor response. In SSG VIII a total replacement 
strategy with new agents postoperatively was unsuccessful. The collective current 
data indicate that when faced with a poor histological response to pre-operative 
chemotherapy, the addition of agents is better than altogether replacing the 
previous ones. It is important to realise that limited chemosensitivity as evaluated 
by primary tumour necrosis does not imply chemotherapy resistance at the 
micrometastatic level. SSGVIII and other studies show that even in poor 
responders, survival is elevated well above historical controls treated without 
chemotherapy.  
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2. Further studies on promising agents in clinical use having inadequate 
documentation of efficacy. 
By doing a long term follow-up study of the Karolinska series we have confirmed 
that adjuvant IFN appears to give benefit in OS, but proof of efficacy is still lacking. 
Our attempts to further explore mechanisms of IFN sensitivity and resistance were 
limited by the low sample size and lack of IFN sensitivity in the xenografts. 
In rare tumours with significant mortality there is a natural tendency for 
implementing new and promising drugs too early and outside well-designed clinical 
trials. This highlights the necessity for large cooperative efforts in the sarcoma field, 
as illustrated by the EURAMOS 1 trial, which to some degree addresses the IFN 
question in a randomized fashion. 
 
3. The development of novel (targeted) agents. 
Molecular profiling of sarcoma subtypes will probably have considerable impact in the 
future. Examples to date include the identification of GIST as a separate entity with a 
characteristic genetic alteration which has been targeted with successful treatment. 
Following the human cancer genome project a few critical signalling pathways have 
been identified176. Blocking a malfunctioning signalling network at single or multiple 
points in the cascade appears to be the most promising way forward. Among many 
emerging new agents we have selected Nutlin-3a and strengthened the case for further 
exploration of this substance in MDM2 amplified sarcomas. 
Further improvement in sarcoma survival is dependent on this type of strategy, where 
targeted drug development follows identification of critical signals driving the malignant 
phenotype. However, the increasing complexity of small-volume sarcoma subtypes and 
the aim to develop specific treatments for single tumour entities requires cooperation in 
large networks of expert centres, as established in EURAMOS, EUROEWING, 
CONTICANET and EUROBONET. 
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1BAbstract
Interferons (IFNs) may target cancer cells both through their regulation of the immune 
response, effect on angiogenesis and through direct effect on cancer cells. Treatment response 
has been demonstrated in osteosarcoma patients, but tumour resistance to IFN- is common. 
Hence, understanding the molecular mechanisms involved in response and resistance is 
essential for improving therapeutic efficacy. Of five xenografts screened for specific growth 
delay in response to treatment with unconjugated and PEGylated IFN-2b, one displayed 
growth inhibition and tumour shrinkage. Growth inhibition increased on a dosing schedule of 
PEGylated IFN every third day. Xenografts resistant to PEGylated IFN were similarly 
resistant to unconjugated IFN. Combination treatment with IFN-2b and doxorubicin resulted 
in improved growth control rates. Transcriptional profiling analysis of the one sensitive and 
two resistant xenografts identified a common set of 79 genes significantly affected by IFN-
2b treatment independent of tumour growth inhibition. All but four of the 79 genes were  
up-regulated. The majority of these genes were well characterized IFN-stimulated genes and 
core members of the IFN- signalling pathway. The expression of a set of 128 unique genes 
changed only in the sensitive xenograft; 52/128 genes were  up-regulated. The specific gene-
expression pattern seen in the responsive xenograft identified possible pathways important for 
the antitumor effect of IFN- in osteosarcoma, including ssubsets of genes involved in cell 
adhesion and osteogenic tissue development. The observed improved control rates of 
combined treatment with IFN and doxorubicin are encouraging and should be further 
explored.  
2BKeywords:
Osteosarcoma, xenograft, interferon, gene expression profiling 
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4B ackground
Osteosarcoma (OS) is the most frequent primary malignant tumour of the skeletal system in 
children and young adolescents. Although a multidisciplinary approach with specialized 
surgery and combination chemotherapy has led to significant survival improvement during 
the last three decades, a relapse rate of 30-40% within five years remains  (Souhami et al. 
1997; Bacci et al. 2000; Bielack et al. 2002; Smeland et al. 2003; Ferrari et al. 2005). Further 
improved survival appears to depend on the optimal integration of novel drugs into the 
existing treatment protocols.  
Interferons (IFN) are biological response modifiers that may inhibit cancer cell growth by 
regulation of the immune response, inhibition of angiogenesis and direct antitumour activity  
(Balkwill 1985; Gresser 1989). By interactions with their specific cell surface receptors IFNs 
activate signal transducer and activator of transcription (HSTATH) complexes and initiate the 
classical HJanus kinaseH-STAT ( HJAK-STAT H) signalling pathway  (Fu et al. 1992; Schindler et 
al. 1992). Activated STATs form complexes that bind to specific IFN-stimulated response 
elements (ISRE) or IFN--activated site (GAS) elements within promoters of interferon 
stimulated genes (ISGs) to initiate transcription. In addition, non-classical signalling 
(involving MAPK, PI3K and NF-B) is necessary to explain the full extent of the 
transcriptional gene response  (Platanias 2005; Du et al. 2007). 
IFN- subtypes differ in their binding affinities to the IFN receptor and also have variable 
efficacy on tumour growth  (Balkwill 1985; Foster and Finter 1998; Yamaoka et al. 1999). 
Whereas the early studies were performed with mixtures of IFNs extracted from white blood 
cells, most clinical trials have been performed with single-species recombinant IFN-and 
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more recently with variants conjugated to poly-ethylene-glycol (PEGylation). PEGylation 
delays the elimination of IFN, allowing for once weekly treatment in humans  (Glue et al. 
2000), and carries a promise of higher efficacy and reduced toxicity  (Eggermont et al. 2008). 
Direct antitumour activity in osteosarcoma has been demonstrated in vitro  (Strander and 
Einhorn 1977; Dannecker et al. 1985) and in vivo  (Masuda et al. 1983; Hofmann et al. 1985; 
Brosjo 1989). Pioneering work at the Karolinska Hospital in Stockholm strongly indicated 
single agent activity of adjuvant human IFN-in patients with non metastatic high-grade 
osteosarcoma  (Muller et al. 2005; Strander 2007). No clear benefit of IFN- was observed in 
the only completed randomized trial testing the additional effect of IFN following 
conventional chemotherapy  (Winkler et al. 1984). EURAMOS1, a major randomized OS trial  
(EURAMOS) explores sequential maintenance treatment with PEGylated IFN-2b for the 
favourable prognostic subgroup with good histologic response to neoadjuvant chemotherapy 
with cisplatinum, doxorubicin and high-dose methotrexate. Although IFN is in some clinical 
use in advanced osteosarcoma, the relative contributions of direct antitumour effects, 
inhibition of angiogenesis and indirect immune-mediated effects are not known. Resistance to 
IFNis frequently seen, and an understanding of the molecular mechanisms involved in 
response and resistance is essential for improving the therapeutic efficacy. Furthermore, IFN-
 has been effective in the treatment of multidrug resistant osteosarcoma cell lines (Manara et 
al. 2004) and may be a way to overcome chemotherapy resistance. We therefore investigated 
the growth response of PEGylated IFN-2b and unconjugated IFN-2b treatment and the 
effect of PEGylated IFN-2b  on gene expression in osteosarcoma tissue using human 
xenograft models. Finally, aiming at integrated bio-chemotherapy, we extended our 
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experimental series by combining IFN treatment with doxorubicin, which is one of the four 
active drugs in OS treatment  (Blaney et al. 1993). 
 
5BMaterial and methods 
80BAnimals
Female athymic mice (Balb/c: nu/nu) were bred in our animal facility, weaned after 21 days 
and maintained in a pathogen-free environment at controlled temperature (21 +/- 0.5C) and 
humidity (55-65%) on a 12 hour light cycle. Sentinels were tested according to FELASA’s 
health monitoring recommendations. Groups of up to eight mice were kept in transparent 
polycarbonate cages (Tecniplast Eurostandard type III, Scanbur BK, Nittedal, Norway) on 
aspen chip bedding (B&K Universal, Hull, UK) with pellet feed (RM3, Special Diets 
Services, Witham, UK) and acidified water supplied ad libitum. Morbidity was controlled for 
by daily inspections focusing on behaviour, posture or weight loss. Animals were sacrificed 
for ethical reasons in case of weight loss >10% or tumour diameter >20 mm. Before 
transplantation or sacrifice by cervical dislocation mice were anaesthetised with 
intraperitoneal injection of 0.1mg/kg fentanyl, 5 mg/kg fluanison (Janssen Pharmaceutica, 
Beerse, Belgium), and 2.5 mg/kg midazolam (Roche, Basel, Switzerland). 
All procedures involving animals were performed according to protocols approved by the 
National Research Authority in compliance with the European Convention for the Protection 
of Vertebrates Used for Scientific Purposes.  
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81BXenografts
Tumour fragments were sampled from adolescent high grade osteosarcomas, four from 
primary tumours (TSx, KPBx, OHSx, MPAx) and one from a pulmonary metachronous 
metastasis (HPBx). Tumour tissue was implanted in the flanks of nude mice and propagated 
by serial transplantation  (Bruheim et al. 2004).  
The mice were allocated to treatment groups when tumours reached 50-70 μl. Tumours were 
measured twice weekly and tumour volumes calculated as 0.5 x length x width2. Relative 
tumour volume (RTV) was calculated for each individual tumour for a specific number of 
days after start of treatment: RTV = Volumeday X *100 / Volumeday 0. Tumour doubling time 
(TD) was defined as the time from the start of treatment to the first doubling of the median 
RTV. The drug effect was expressed as specific growth delay SGD = (TDtreated – TDcontrol)/ 
TDcontrol and treated to control rate T/C (%) = RTVtreated x 100 / RTVcontrol. Based on earlier 
experience SGD of > 1.0 and T/C of < 50% were defined as antitumour activity  (Bruheim et 
al. 2004) 
82BRadio-labelling of PEGylated IFN 
To estimate elimination half life in mouse serum, PEGylated IFN was radio-labelled with 125I. 
For this analysis, PEGylated IFN was radio-labelled with 125I at an equimolar ratio. An 
Iodogen tube (Pierce) was prewashed with 1 ml of a pH 7.5 iodination buffer (25 mM Tris, 
0.4 M NaCl, all Sigma). 30 l iodination buffer and 20 MBq 125I dissolved in 7 l water was 
added to the iodination tube and incubated for 5 min under continuous shaking, transferred to 
a tube containing 50 g interferon- in 50 l water and incubated for another 5 min. 
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Iodination was terminated by adding 50 l of iodination buffer with 10 mg/ml of tyrosine 
(Sigma). Finally free and bound iodine were separated on a column (Paus et al. 1982).  
Eight mice were randomly assigned to two groups. Mice were pre-treated with potassium 
iodide 10 g/day in the drinking water for 5 days before subcutaneous injection with 125I-
labeled PEGylated interferon-	b at 10 and 100 g/kg (0.3 and 3 MBq). Each mouse was 
sampled daily for 20-40 l blood with a heparinised microcapillary (capillary tubes for 
microhematokrit, art. Nr. 110690, Kebo-Lab Stockholm) (Hem et al. 1998). At the indicated 
time points (24 h, 7 days) mice were anesthetized, cardially aspirated and killed before 
sampling tumour-tissue and hind leg muscle. Serum was spun for 7 minutes at 12 800 rpm in 
a Hematokrit 24 centrifuge (Hettich Zentrifugen), diluted in PBS, and tissue samples were 
minced in PBS before filtration on a NAP-5 column (Pharmacia Biotech) equilibrated with 
PBS, and the radioactivity was counted in a Wallac automatic gamma counter (Perkin Elmer 
Life Science) together with samples of known activity. We found excellent correlation 
between the capillary plasma and cardial serum measurements (r = 0.99). 
83BDrugs
Unconjugated IFN-2b (Intron A, Schering Plough, Oslo, Norway, specific activity 2.6x108 
IU/mg protein) was administered using a prefilled injection pen. MonoPEGylated IFN-2b 
(PEG-INTRON®, Schering Plough, specific activity 6.4x107 IU/mg protein) was reconstituted 
in water. Stock solutions of diluted PEGylated IFN were stored for a maximum of 2 weeks at 
-80C. Immediately before use the stock was diluted with PBS + BSA  (Sanceau et al. 2002) 
to the final concentration in a volume of 0.1 ml. IFNs were injected subcutaneously (s.c.) to 
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the lower back of the mice. Control mice were treated with s.c. PBS + BSA. Doxorubicin 
(Adriamycin, Pharmacia Upjohn, Stockholm, Sweden) was dissolved in physiological saline 
and administered intravenously (i.v.).  
Unconjugated IFN was administered at daily doses of 30,000, 300,000 or 1 million IU/mouse 
(equivalent to weekly doses of 40, 400or
g/kg). PEGylated IFN was tested at weekly 
doses of 10, 100 or 300 g/kg or every third day at an equivalent dose of 4.3, 43 
or
	g/kg. The total treatment interval for IFN was 3 weeks. Combined treatment with IFN 
and doxorubicin was started with 10 or 100 g/kg/week PEGylated IFN followed 24 hours 
later by 8mg/kg doxorubicin equalling the maximal tolerated dose (Bruheim et al. 2004); the 
doxorubicin injection was repeated once after a week.  
For microarray experiments mice were treated with 100 g/kg PEGylated IFN-2b and the 
tissue were sampled both 24 and 48 hours later. In the combination group, mice were treated 
with 100 g/kg PEGylated IFN-2b, followed 24 hours later by 8 mg/kg doxorubicin. Tissue 
was sampled 24 hours after the doxorubicin treatment. 
84BGene expression microarray analysis 
RNA isolation, labelling and microarray hybridizations. Tissue samples were snap frozen on 
liquid nitrogen and stored at -80°C until use. Total RNA was extracted using TRIzol 
(Invitrogen, Carlsbad, CA, USA) and stored at -80°C. Samples were quantified on a 
NanoDrop spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA) and 
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RNA integrity was determined on Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, 
USA). RNA from several animals was pooled. In the initial experiments hybridizations were 
done on cDNA arrays printed at the core facility of the Norwegian Microarray Consortium at 
the Norwegian Radium Hospital (Oslo, Norway) as described earlier (Prasmickaite et al. 
2006). For the final experiments amplification and labelling of 500 ng RNA from treated and 
untreated TSx, MPAx and HPBx xenografts was performed using the Illumina TotalPrep 
RNA amplification kit (Illumina Inc., San Diego, CA, USA). The microarray experiments 
were done using the Whole-Genome Gene Expression Direct Hybridization Assay and 
Illumina Human-6 Expression BeadChips version 2 arrays (Illumina Inc.) consisting of 
>48,000 different probes represented with an average 30-fold redundancy across the array. 
Technical replicates were hybridized for all samples. All laboratory processing and 
hybridisations were performed according to manufacturer’s protocols.  
Microarray pre-processing and analysis. The slides were scanned with the BeadArray 
Reader (Illumina, Inc.) and data extraction and initial quality control of the bead summary 
raw data were performed using BeadStudio (version 3.1.3.0) from Illumina and the Gene 
Expression module 3.2.6. Additional quality control before and after quantile normalization 
and pre-processing was performed with the R package (Du et al. 2007; Du et al. 2008; Lin et 
al. 2008) which is a part of the Bioconductor project (R-Development-Core-Team 2009) and 
the data was annotated using the HumanWG-6_V2_R4_11223189_A annotation file from 
Illumina. Changes in gene expression were detected at the probe level with one gene 
represented by one or several probes. To find probes that were differentially expressed 
between IFN treated and untreated samples for each of the xenografts, we applied linear 
models for microarray data (Limma) significance analysis with a moderated t-statistic using a 
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simple Bayesian model (Smyth 2004). The cut-off value for log2-fold-change was set to 0.57 
(fold- change <1.5) and the p-value was adjusted for multiple testing by Benjamini and 
Hochberg’s method  (Benjamini and Hochberg 1995) with restriction p <0.01. When 
identifying probes related to IFN resistance, the difference in expression levels between the 
sensitive and each of the resistant xenografts had to be at least 1.5 fold. The discriminatory 
gene lists were further analysed in the online Database for Annotation, Visualization and 
Integrated Discovery (DAVID, release 2008)  (DAVID ; Dennis et al. 2003) to organize the 
genes and identify enrichment based on common functional features in KEGG biochemical 
pathways and Panther ontologies Biological Process and Molecular Function. To measure the 
gene-enrichment in annotation terms the number of genes on the differentially expressed lists 
were compared to all the genes on the Illumina array. The significance of enrichment was 
indicated by p-values calculated as EASE score  (Hosack et al. 2003), a modified Fisher Exact 
P-Value for gene enrichment analysis, and the cut-off was set to p <0.01. The data was 
submitted to ArrayExpress with accession E-TABM-707.  
Interferome, a recently published database of ISGs and putative ISRE in the promoters of 
these genes  (Interferome ; Samarajiwa et al. 2008) was used to investigate IFN signatures in 
the gene lists of differentially expressed genes.  
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6BResults
85BTreatment response of the xenografts 
Of a total of five osteosarcoma xenografts screened for growth inhibition in response to 
treatment with PEGylated IFN-2b, only one (HPBx) was found to be sensitive (Figure 1). 
Xenografts resistant to PEGylated IFN were also resistant to treatment with unconjugated IFN 
(Figure 1; G, H). In the sensitive xenograft (HPBx), weekly administration of 100 g/kg 
PEGylated IFN gave a weak response (specific growth delay of 0.25 and a treated to control 
rate of 69% (Figure 1C). Due to strong growth inhibition of unpegylated IFN in the same 
xenograft (Figure 1A), we examined the half life PEGylated IFN in our model. Iodination of 
PEGylated IFN indicated a half-life of 15-16 hours in nude mice, compared to 27-39 hours in 
humans  (Glue et al. 2000) (Figure 2). An adapted treatment schedule of PEGylated IFN 
every third day at a dose equivalent of 100 and 300 g/kg/week improved efficacy compared 
to weekly administrations and strongly suppressed tumour growth (specific growth delay of 
1.25 and 7.5; treated to control rate of 15% and 5%, Figure 1B . Daily treatment with 
unconjugated IFN at a dose equivalent of 40g/kg/week (30,000 IU/mouse/day) was less 
effective (specific growth delay of 0.75 and a treated to control rate of 30%) whereas a dose 
of 400g/kg/week (300,000 IU/mouse/day) for 21 days prevented any regrowth of the 
sensitive xenograft for a period of at least 90 days after end of treatment. We observed a dose-
response relationship for both agents (Figure 1B).  
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Combined treatment with doxorubicin and PEGylated IFN. Pilot experiments were 
performed examining the potential of concomitant treatment of the sensitive xenograft 
(HPBx) with IFN and doxorubicin. When the IFN-sensitive xenograft HPBx was treated with 
8 mg/kg doxorubicin as monotherapy a moderate growth delay was obtained (specific growth 
delay 1.25, treated to control rate 44%). Treatment with PEGylated IFN followed by 
doxorubicin 24 hours later was considerably more effective than monotherapy with either 
doxorubicin or IFN (specific growth delay up to 2.5, treated to control rate of 26%; Figure 
1D).  
86BResponse in gene expression  
Initial analyses of time course and dose response. Initial experiments were performed to 
investigate the time course and dose-dependence of the response to PEGylated IFN (Figure 
3). Known ISGs were among the strongest induced, and showed highest expression levels 
with the highest dose and peaked within 12-24 hours. Based on these initial results we 
selected a dose of 100 μg/kg PEGylated IFN for 24 hours for further experiments with the 
three xenografts HPBx, TSx and MPAx, representing the one sensitive and two resistant 
xenografts, respectively. 
Global changes in gene expression. Treatment with PEGylated IFN caused a significant 
change in the expression detected by 300 probes in HPBx, 325 in TSx and 1,777 in MPAx 
when comparing the treated and untreated xenografts pair-wise. The probe lists were filtered 
to identify probes that were specific for the sensitive and resistant xenografts (see 
Supplementary Tables 1, 2, 3) and were further classified according to biological and 
functional characteristics (Supplementary Table 4).  
15 
 
Genes affected by IFN in all xenografts. Ninety-nine of the probes detecting significant 
expression changes upon IFN treatment were common for all three xenografts. Five of these 
probes showed opposite effects in some of the three xenografts and were removed. This 
resulted in a set of 94 probes, representing 79 genes; 75 genes were up-regulated and only 
four were down-regulated in all xenografts. Mean fold change for these genes were 2.4, 6.6 
and 3.9 in HPBx, TSx and MPAx, respectively (Supplementary Table 1).  
This group contains several core members of the IFN signalling pathway (STAT1, ISGF3G, 
IRF7) and central well characterized ISGs (OAS1-3, MX1, EIF2AK2, members of the HLA 
and PARP families, and ISG15) (Supplementary Table 1). As expected, these genes were 
enriched in immunity related gene ontology groups and pathways (Supplementary Table 4A).  
Sixty-six of the 79 common genes were identified as known ISGs in the Interferome database  
(Interferome ; Samarajiwa et al. 2008). Thirty-six of these 66 genes were found to contain 
putative ISRE and 16 had a putative STAT1 binding site in the promoter. The high number of 
ISRE-containing genes illustrates the induction of a specific IFN response in all three 
xenografts examined. For the majority of genes, this effect of IFN treatment was more 
pronounced in the resistant xenografts. 
Genes differentially expressed only in the sensitive xenograft. One hundred and twenty-eight 
probes identified genes that were differentially expressed upon treatment with PEGylated 
IFN- only in the sensitive xenograft HPBx . 72 of these probes, representing 70 unique 
genes, had a fold-change difference of  1.5 between the sensitive and each of the two 
resistant xenografts. 24 of these genes were induced and 48 were repressed. Only seven of 
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these genes were identified as known ISGs by the Interferome database and only one of the 
seven had a putative ISRE in the promoter (Supplementary Table 2). 
The 70 genes were significantly enriched for gene ontology annotations related to signalling 
(MF00016) and receptors (BP00108), extracellular matrix (MF00179) and actin binding 
protein (MF00262), development (BP00193) or cell adhesion (BP00124) and KEGG pathway 
calcium signalling pathway (hsa04020) (Supplementary Table 4B).  
IFN down-regulated a number of genes related to the extracellular matrix of connective tissue 
and its maturation, including the collagens COL2A1, COL9A1 and COL10A1, osteomodulin 
(OMD), matrilin 4 (MATN4), and metallopeptidase 3 (MMP3). The adhesion receptor 
galectin-7 (LGALS7) and LOC728910 similar to galectin-7 is down-regulated whereas 
galectin-9 (LGALS9) and the highly similar LGALS9C are  up-regulated.  
Up-regulated genes related to developmental processes included chordin-like 2 (CHRDL2) 
involved in osteo- and myoblast differentiation and T1560 involved in thyroid development. 
Down-regulated genes included the Wnt pathway inhibitor dickkopf1 (DKK1), chordin 
(CHRD) which is an inhibitor of bone morphogenetic proteins, SRY (sex determining region 
Y)-box 8 (SOX8) involved in pro-osteoblast differentiation, secretoglobin (SCGB3A2) 
involved in lung development, and the tyrosine kinase receptor ephrin-A1 (EFNA1) involved 
in development, tumourigenesis and metastasis.  
Genes with similar IFN response in the two resistant xenografts. Of the probes detecting 
significant expression changes, 58 were common only to the two resistant xenografts TSx and 
MPAx, but not significantly changed in the sensitive HPBx. Only 19 of these probes, 
representing 17 unique genes, were similarly regulated in both resistant xenografts and had a 
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fold-change above 1.5 when compared to the sensitive xenograft (Supplementary Table 3). 
Eight of these genes are known as ISGs in the Interferome database of which one had a 
putative ISRE and five a putative STAT1 promoter binding site. Functional annotation 
analysis yielded enrichment in the Panther ontology group MF00001: receptor.  
Gene expression analysis of combination of doxorubicin and PEGylated IFN. Limma 
analyses revealed no significant differences in the gene expression patterns of the xenografts 
treated with IFN alone compared to the combination with doxorubicin at the time point 
investigated (data not shown).  
7BDiscussion
87BThe effect of IFN on tumour growth 
In an earlier series of 14 osteosarcoma xenografts in nude mice, natural buffy coat-derived 
IFN- at a daily dose of 200,000 IU induced tumour regression or growth arrest in five, 
partial growth inhibition in eight whereas one tumour could only be arrested at a higher dose 
(Brosjo 1988). In contrast, in this report only one of five xenografts were sensitive to 
PEGylated IFN-2b. This may be explained by differences in the tumour panels or the 
therapeutic agents. It may be relevant that three of our tumours (including the sensitive one) 
were exposed to chemotherapy before xenografting, whereas all the Karolinska tumours were 
chemotherapy naïve. The sensitive xenograft being the only one of metastatic origin is an 
observation of uncertain significance: small series with IFN in metastatic osteosarcoma did 
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not indicate clinically relevant efficacy. Furthermore, our xenograft lines were maintained 
over a longer time before the experiments. Although passage number did not seem to affect 
response to chemotherapy in a previous study on this panel  (Bruheim et al. 2004), we can not 
exclude that primary IFN resistance may be caused by passage-related genetic or epigenetic 
alterations over time. As human IFNs are not thought to evoke a host response in mice  
(Balkwill 1985), it seems unlikely that a different immune status of our animals would 
explain the different treatment response. 
The difference may also be due to the type of IFNs used. Natural IFN, as used in the 
Karolinska experiments, contains a mixture of -interferon subtypes that have varying 
properties and anti-proliferative activity  (Thomas and Balkwill 1991; Foster et al. 1996; 
Foster and Finter 1998; Yano et al. 2006). It is also possible that PEGylation may directly 
influence the antitumour effect. Natural -IFNs have been shown to have higher anti-tumour 
activity in a small panel of osteosarcoma xenografts compared with recombinant IFN-2c  
(Bauer et al. 1987), but have not been directly compared with PEGylated IFN-. 
Unconjugated and PEGylated IFN-2a induced similar growth inhibition and expression 
profiles in melanoma-xenografts  (Certa et al. 2003; Krepler et al. 2004), whereas growth 
inhibition in hepatocellular carcinoma xenografts was stronger for PEGylated IFN-2b  
(Yano et al. 2006). Significant variation in the IFN-related response depending on the targeted 
cell line and IFN– subtype has been reported by others  (Balkwill et al. 1985; Foster and 
Finter 1998; Yamaoka et al. 1999; Yanai et al. 2001). In our panel, xenografts resistant to 
PEGylated IFN were similarly resistant to unconjugated IFN. Complete growth arrest in the 
sensitive xenograft was only obtained by unconjugated IFN, but this could be due to the 
higher dose administered per week compared to the PEGylated moiety. Importantly, lack of 
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effect in our model system on tumour growth is only reflecting the absence of a direct 
antitumour effect of IFN and does not rule out clinically important effects mediated through 
immune- or angiogenesis-mediated mechanisms.  
88BChanges in gene expression in response to IFN 
With only one sensitive xenograft, we limited the microarray analysis to compare the one 
sensitive to two resistant xenografts. Obviously such a limited analysis cannot provide 
definite answers, but may indicate a list of candidate genes and pathways related to IFN 
treatment response. We restricted the investigation of the transcriptional response to 
stimulation with PEGylated IFN, as previous studies have shown that unconjugated and 
PEGylated IFN give indistinguishable transcriptional patterns and are equally potent 
activators of IFN gene expression  (Certa et al. 2003; Krepler et al. 2004).  
When comparing the sensitive and the resistant osteosarcoma xenografts we identified 79 
genes with similarly altered expression after IFN treatment regardless of tumour response. A 
subset of 36 genes contained ISRE, indicating a functional JAK/STAT signalling pathway in 
all three xenografts. Genes exclusively induced in the sensitive xenograft rarely contained 
ISRE; a comparable group of genes was observed earlier in an IFN sensitive melanoma cell 
line and termed IFN secondary response genes  (Certa et al. 2003). It was postulated that 
resistance to IFN is caused by abnormal secondary signalling rather than by primary defects 
in induction of JAK-STAT signalling pathway  (Certa et al. 2003; Holko and Williams 2006). 
LGALS9, and the similar LGALS9C, are among the ISGs induced by IFN in the sensitive 
xenograft. Galectins are evolutionary highly conserved -galactoside-binding lectins involved 
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in basic cellular mechanisms (cell interaction, proliferation, migration, apoptosis, mRNA 
splicing) and modulation of immunity. LGALS9 expression is correlated with a better 
prognosis in malignant melanoma  (Kageshita et al. 2002), and is possibly involved in IFN-
induced apoptosis in the melanoma cell line WM9  (Leaman et al. 2003). Two other members 
of the galectin family, LGALS7 and LOC728910, were found to be down-regulated, and these 
proteins have previously been described both as a positive and negative regulatory factors in 
tumour development, involved in proapoptosis, neoangiogenesis and metastatic tendency 
through metastatic proteins such as MMP9  (Saussez and Kiss 2006).  
IFN- has been shown to induce bone differentiation in a xenotransplanted human 
osteosarcoma  (Forster et al. 1988). Osteosarcomas are known to express several bone 
morphogenetic proteins (BMPs)  (Bauer and Urist 1981; Gobbi et al. 2002; Khan et al. 2008), 
the central proteins in the fine-tuning of bone development. Both CHRD, a regulator of 
dorsoventral patterning in early embryogenesis, and CHRDL2, a structurally related protein 
expressed preferentially in chondrocytes of developing cartilage, are BMP binding inhibitors 
of bone differentiation  (Zhang et al. 2007). In our sensitive xenograft, IFN induced up-
regulation of CHRDL2 whereas CHRD was down- regulated, the significance of which is 
unclear.  
Further, the transcription factor SOX8 was repressed as a response to IFN treatment. SOX8 is 
involved in early chondrogenesis and SOX8-deficient mice display an osteopenic phenotype. 
SOX8-deficient preosteoblasts proliferate slowly probably caused by RUNX2-induced exit 
from the cell cycle  (Schmidt et al. 2005), and the reduced expression of SOX8 may thus be 
related to the tumour response. 
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Finally, DKK1 was down-regulated following IFN treatment in the sensitive xenograft only. 
DKK1 inhibits Wnt signalling and impairs osteoblast function. DKK-1 has been shown to be 
expressed maximally at the periphery of the tumour and it is thought that DKK1 can 
contribute to tumour expansion by inhibiting repair of the surrounding bone  (Lee et al. 2007). 
Osteosarcoma patients have elevated DKK1 serum levels and the surviving fraction of 
circulating osteosarcoma cells is proportional to DKK1 levels in a xenograft model  (Lee et al. 
2007); it has been suggested that DKK1 levels could be used to monitor the effect of 
osteosarcoma treatment, and this might be applicable also to interferon. However, our 
findings contrast in vitro data of interferon induced overexpression of DKK1 in a 
hepatoblastoma cell line  (Qu et al. 2007) .  
In summary, several genes involved in cell adhesion and osteogenic tissue development were 
altered by IFN in the sensitive xenograft. However, the analysis of only one sensitive 
xenograft, and the fact that the magnitude of change in these genes appeared low, makes 
caution in the interpretation imperative. 
Our observations that combined treatment with IFN and doxorubicin has an increased efficacy 
indicate that IFN may moderate response to other cytotoxic drugs. An exploratory analysis 
did not find transcriptional changes of combined IFN and doxorubicin as compared to IFN 
alone. Doxorubicin has been shown to induce both cell cycle regulators and death genes in 
hepatocellular cancer cell lines (Wang et al. 2009). The lack of specific mRNA changes in 
this report may point at a posttranscriptional regulation by the combination in the sensitive 
xenograft. Others have shown that one of the many genes induced by IFN is the tumour 
suppressor TP53  (Takaoka et al. 2003), and that IFN-related genes such as ISGF3G directly 
influence p53 expression  (Munoz-Fontela et al. 2008). Doxorubicin can induce apoptosis 
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through p53 in osteosarcoma cells  (Yuan et al. 2007; Yuan et al. 2008). In this study, no 
change in TP53 mRNA levels was observed between IFN treated and untreated osteosarcoma 
xenografts, but we cannot rule out effects at the protein level. Finally, it has been shown that 
IFN- can mobilise quiescent leukemia stem cells, thus making them sensitive to 
chemotherapy (Essers et al. 2009). It remains to be seen if such mechanisms also can be 
exploited in non-haematological cancers.  
 
 
8BConclusions
We found a direct antitumour effect of IFN in one of five xenografts. At the doses tested, both 
types of IFN reduced the growth rate, but only unconjugated interferon induced growth arrest. 
Known ISGs were induced independent of tumour response. The antitumor response seen in 
one xenograft may be related to interference with genes involved in cell adhesion or 
osteogenic tissue development. Our preliminary data of combined treatment with IFN and 
doxorubicin are encouraging and should be further explored. 
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79BFigure legends 
89BFigure 1 
Growth response of osteosarcoma xenografts to treatment with PEGylated IFN (PEG-IFN), 
unpegylated IFN (IFN), doxorubicin (DOX) or a combination of DOX-IFN compared to a 
control group (CTR). Doses are given in equivalents to g/kg/week. IFN was always given 
daily. PEG-IFN was given weekly in Figure A, C, D, E and F and every third day in Figure B, 
G, H. Doxorubicin was given at the maximal tolerated dose of 8 mg/kg 24 hours after start of 
treatment with PEG-IFN 100 (DOX-IFN). Volume is annotated as median relative tumour 
volume (RTV). 
Figure 2 
Elimination half-life of PEGylated IFN in mouse serum. 
Serum concentration of radiolabeled PEGylated IFN-	b inNCR mice following a single 
treatment with a dose of 10 and 100 g/kg. 
90BFigure 3 
Hierarchical clustering of gene expression patterns in initial time and dose response 
experiments. A. 369 differentially expressed probes in xenograft TSx treated with 100 
μg/kg/week PEGylated IFN-2b for 12, 24 and 48 hours. B. Expanded view of lower 
31 
 
subcluster (red) from A, showing induction of numerous interferon-regulated genes C. 168 
differentially expressed probes in xenograft TSx treated with 1, 10 or 100 μg/kg/week 
PEGylated IFN-2b for 24 hours. An untreated control sample (TSx Ctrl) was also included. 
The signal of each probe is given as log2 of the ratio between the treated and untreated 
samples that was co-hybridized to the arrays, represented as mean value of two replicated 
assays. The probes presented in the clusters were at least 2 times up- or down-regulated in at.  
91BSupplementary files 
Supplementary table 1 
Tab delimited textfile .txt 
Differentially expressed probes common in three xenografts. 
Relative intensity level of 94 probes (log2 ratios) that detected a common gene expression 
response in HPBx, TSx and MPAx following treatment with 100 μg/kg PEGylated IFN-	b 
for 24 hours. The cut-off for the Limma analysis was set to p<0.01 and and fold-change <1.5 
(log2 fold-change< 0.585). IFN-regulated genes (in bold) and putative ISRE and STAT1 
binding sites in proximal promoter regions 1000 bp upstream of the transcription start site and 
the 5’UTR of the genes was identified in the Interferome database.  
Supplementary table 2 
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Tab delimited textfile .txt 
Differentially expressed probes in the sensitive xenograft only. 
Relative intensity level of 72 probes (log2 ratios) that detected differentially expressed genes 
in the sensitive xenograft HPBx, but not in the resistant xenografts TSx and MPAx following 
treatment with 100 μg/kg PEGylated IFN-	b for 24 hours. The cut-off for the Limma 
analysis was set to p<0.01 and and fold-change <1.5 (log2 fold-change< 0.585).  In addition 
the difference in expression level between the sensitive and each of the resistant xenografts 
was at least 1.5 fold. IFN-regulated genes (in bold) and putative ISRE and STAT1 binding 
sites in proximal promoter regions 1000 bp upstream of the transcription start site and the 
5’UTR of the genes was identified in the Interferome database. 
Supplementary table 3 
Tab delimited textfile .txt 
Differentially expressed probes in two resistant xenografts 
Relative intensity levels (log2 ratios) of 19 probes representing genes that were differentially 
expressed in both of the resistant xenografts TSx and MPAx, but not in the sensitive xenograft 
HPBx following treatment with 100 μg/kg PEGylated interferon-	b for 24 hours. The cut-
off for the Limma analysis was set to p<0.01 and fold-change <1.5 (log2 fold-change< 0.585). 
In addition the difference in expression level between the sensitive and each of the resistant 
xenografts was at least 1.5 fold. IFN regulated genes (in bold) and putative ISRE and STAT1 
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binding sites in proximal promoter regions 1000 bp upstream of the transcription start site and 
the 5’UTR of the genes was identified in the Interferome database.  
92BSupplementary table 4 
Adobe Acrobat Document .pdf 
 
Metabolic pathways representing genes overrepresented among those with altered 
expression. Pathways are shown that appeared enriched using ontologies from Panther 
Biological Process (BP), Molecular function (MF) and KEGG pathwaysa. Enriched categories 
from analysis of A: 94 probes with similar IFN response in HPBx, TSx and MPAx. B: 70 
probes differentially expressed in the sensitive xenograft HPBx only. C: 19 probes with 
similar IFN response in the resistant xenografts TSx and MPAx. 
Figure 1 Growth response of osteosarcoma xenografts
Figure 2 Elimination half-life of PEGylated IFN in mouse serum
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Figure 3 Hierarchical clustering of gene expression patterns in initial time and dose 
response experiments
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Supplementary Table 1.  Differentially expressed probes common in three xenografts
ILMN_Gene Source_Reference_ID
Definition
log2FC 
HPBx/HPXCtrl
log2FC 
TSx/TSxCtrl
log2FC 
MPAx/MPAxCtrl ISRE STAT1
ACO1 NM_002197.1 aconitase 1, soluble -0.665 -0.708 -0.948
ADAR NM_015840.2 adenosine deaminase, RNA-specific 0.681 1.212 0.809
ASPN NM_017680.3 asporin -0.853 -1.039 -1.209
B2M NM_004048.2 beta-2-microglobulin 1.136 1.248 1.423 x
BST2 NM_004335.2 bone marrow stromal cell antigen 2 1.619 4.573 1.506 x x
CD68 NM_001251.1 CD68 antigen 1.016 1.673 1.134
CFB NM_001710.4 complement factor B 1.137 1.401 1.745 x
DDX58 NM_014314.2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.690 1.434 1.581 x
DTX3L NM_138287.2 deltex 3-like (Drosophila) 0.747 1.606 1.003 x x
EIF2AK2 NM_002759.1 eukaryotic translation initiation factor 2-alpha kinase 2 0.715 1.551 1.022 x
EPSTI1 NM_033255.2 epithelial stromal interaction 1 (breast) 1.613 2.928 2.443 x
FLJ11000 NM_018295.1 hypothetical protein FLJ11000 0.703 0.593 1.279 x x
FLJ11286 NM_018381.1 hypothetical protein FLJ11286 0.801 1.757 1.607
FLJ20035 NM_017631.3 hypothetical protein FLJ20035 1.074 2.291 1.078 x
G1P3 NM_002038.2 interferon, alpha-inducible protein (clone IFI-6-16) 0.955 2.393 1.898 x x
GBP1 NM_002053.1 guanylate binding protein 1, interferon-inducible, 67kDa 1.194 0.87 1.306 x
HCP5 NM_006674.2 HLA complex P5 1.927 1.215 1.801
HERC5 NM_016323.1 hect domain and RLD 5 0.841 2.766 0.939 x
HERC6 NM_001013005.1 hect domain and RLD 6 1.935 4.498 3.123
HES4 NM_021170.2 hairy and enhancer of split 4 (Drosophila) 0.603 1.654 1.543
HLA-A NM_002116.5 major histocompatibility complex, class I, A 1.075 0.737 1.405 x
HLA-B NM_005514.5 major histocompatibility complex, class I, B 2.425 1.72 2.424 x
HLA-C NM_002117.4 major histocompatibility complex, class I, C 1.657 1.345 1.652 x
HLA-E NM_005516.4 major histocompatibility complex, class I, E 1.652 0.819 1.927
HLA-F NM_018950.1 major histocompatibility complex, class I, F 2.072 1.544 1.258 x
HLA-H NR_001434.1 major histocompatibility complex, class I, H (pseudogene),non-
coding RNA. 1.127 1.183 1.656
HS.125087 Hs.125087 AGENCOURT_7914287 NIH_MGC_71 cDNA clone 
IMAGE:6156595 5, mRNA sequence 1.494 3.798 1.613
HS.371609 Hs.371609 cDNA clone IMAGE:5261213 -0.626 -1.113 -1.278
HS.489254 Hs.489254 cDNA clone IMAGE:5277162 0.836 0.902 0.697
IFI27 NM_005532.3 interferon, alpha-inducible protein 27 1.824 3.852 3.869 x x
IFI30 NM_006332.3 interferon, gamma-inducible protein 30 1.276 1.09 1.44
IFI35 NM_005533.2 interferon-induced protein 35 1.442 2.494 2.65 x
IFI44 NM_006417.2 interferon-induced protein 44 1.261 1.99 0.716
IFI44L NM_006820.1 interferon-induced protein 44-like 1.911 5.484 1.686
IFIT1 NM_001548.2 interferon-induced protein with tetratricopeptide repeats 1 1.758 3.687 2.352 x
IFIT2 NM_001547.3 interferon-induced protein with tetratricopeptide repeats 2 1.047 2.809 0.84
IFIT3 NM_001549.2 interferon-induced protein with tetratricopeptide repeats 3 1.740 3.425 1.102 x
IFIT3 NM_001549.2 interferon-induced protein with tetratricopeptide repeats 3 1.910 3.849 2.996 x
IFIT3 NM_001031683.1 interferon-induced protein with tetratricopeptide repeats 3 1.336 1.946 1.869 x
IFITM1 NM_003641.2 interferon induced transmembrane protein 1 (9-27) 1.368 4.585 2.9 x
IFITM2 NM_006435.1 interferon induced transmembrane protein 2 (1-8D) 1.554 3.716 1.387 x x
IFITM3 NM_021034.1 interferon induced transmembrane protein 3 (1-8U) 2.541 3.92 1.768
IRF7 NM_004030.1 interferon regulatory factor 7 1.083 2.117 2.135
ISG15 NM_005101.1 ISG15 ubiquitin-like modifier 1.257 4.749 3.305 x
ISG20 NM_002201.4 interferon stimulated exonuclease gene 20kDa 0.831 1.664 2.524 x
ISGF3G NM_006084.3 interferon-stimulated transcription factor 3, gamma 48kDa 0.663 1.689 1.47
LAP3 NM_015907.2 leucine aminopeptidase 3 0.770 0.864 1.181 x x
LBA1 XM_940627.1 PREDICTED: lupus brain antigen 1 0.683 1.894 0.679
LGALS3BP NM_005567.2 lectin, galactoside-binding, soluble, 3 binding protein 0.932 3.245 2.708 x
LGP2 NM_024119.1 likely ortholog of mouse D11lgp2 0.794 2.246 1.547 x
LOC129607 NM_207315.1 hypothetical protein LOC129607 1.033 0.617 1.596
LY6E NM_002346.1 lymphocyte antigen 6 complex, locus E 0.859 3.629 1.446
MX1 NM_002462.2 myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse) 1.557 6.066 2.395 x
OAS1 NM_001032409.1 2',5'-oligoadenylate synthetase 1, 40/46kDa 1.987 3.768 3.002 x
OAS1 NM_002534.2 2',5'-oligoadenylate synthetase 1, 40/46kDa 1.954 0.915 2.796 x
OAS1 NM_016816.2 2',5'-oligoadenylate synthetase 1, 40/46kDa 0.622 1.309 0.826 x
OAS2 NM_016817.2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.007 1.24 1.062 x
OAS2 NM_016817.2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.725 4.345 3.617 x
OAS2 NM_001032731.1 2'-5'-oligoadenylate synthetase 2, 69/71kDa 0.924 2.616 1.795 x
OAS2 NM_002535.2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.244 1.199 2.22 x
OAS3 NM_006187.2 2'-5'-oligoadenylate synthetase 3, 100kDa 1.525 2.767 3.052 x
OASL NM_003733.2 2'-5'-oligoadenylate synthetase-like 1.292 3.153 2.497 x
OASL NM_003733.2 2'-5'-oligoadenylate synthetase-like 0.692 1.737 1.527 x
PARP10 XM_937629.1
PREDICTED: poly (ADP-ribose) polymerase family, member 10 1.373 1.845 1.854
PARP10 NM_032789.1 poly (ADP-ribose) polymerase family, member 10 1.170 1.907 1.948
PARP10 NM_032789.1 poly (ADP-ribose) polymerase family, member 10 1.410 1.606 1.913
PARP12 NM_022750.2 poly (ADP-ribose) polymerase family, member 12 1.087 2.48 2.251
PARP14 NM_017554.1 poly (ADP-ribose) polymerase family, member 14 1.241 1.897 1.613
PARP9 NM_031458.1 poly (ADP-ribose) polymerase family, member 9 1.382 2.838 1.883
PLSCR1 NM_021105.1 phospholipid scramblase 1 1.134 2.187 2.046 x x
PRIC285 NM_033405.2 peroxisomal proliferator-activated receptor A interacting complex 
285 0.916 1.345 2.429 x
PSMB8 NM_004159.4 proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) 1.372 0.97 1.524 x
PSMB8 NM_148919.3 proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) 1.201 1.067 1.378 x
PSME1 NM_006263.2 proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 0.737 0.96 1.1
PSME2 NM_002818.2 proteasome (prosome, macropain) activator subunit 2 (PA28 
beta) 0.796 0.663 0.817
RARRES3 NM_004585.2 retinoic acid receptor responder (tazarotene induced) 3 1.850 2.351 1.862
RSAD2 NM_080657.3 radical S-adenosyl methionine domain containing 2 1.827 3.056 2.7 x
SAMD9L NM_152703.2 sterile alpha motif domain containing 9-like 0.888 1.277 1.204 x x
SLC15A3 NM_016582.1 solute carrier family 15, member 3 1.782 1.958 3.215 x
SP110 NM_004510.2 SP110 nuclear body protein 0.695 1.089 1.064 x
SP110 NM_004510.2 SP110 nuclear body protein 1.037 1.613 1.39 x
STAT1 NM_139266.1 signal transducer and activator of transcription 1, 91kDa 1.364 2.584 1.979 x
STAT1 NM_139266.1 signal transducer and activator of transcription 1, 91kDa 1.302 2.743 2.222 x
STAT1 NM_007315.2 signal transducer and activator of transcription 1, 91kDa 1.136 2.28 1.854 x
TAP1 NM_000593.5 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.018 1.5 2.491
TNFSF10 NM_003810.2 tumor necrosis factor (ligand) superfamily, member 10 1.404 1.469 1.215
TRIM22 NM_006074.2 tripartite motif-containing 22 1.784 1.149 2.064
UBA7 NM_003335.2 ubiquitin-like modifier activating enzyme 7 1.155 2.554 1.624
UBE2L6 NM_004223.3 ubiquitin-conjugating enzyme E2L 6 1.176 1.031 2.013
UBE2L6 NM_004223.3 ubiquitin-conjugating enzyme E2L 6 1.067 1.153 2.514
USP18 NM_017414.2 ubiquitin specific peptidase 18 0.641 1.175 0.977 x x
USP41 XM_937988.1 PREDICTED: ubiquitin specific peptidase 41 0.737 1.237 1.142
XAF1 NM_199139.1 XIAP associated factor 1 1.422 1.418 2.112 x
ZDHHC14 NM_024630.2 zinc finger, DHHC-type containing 14 0.705 0.826 0.854
Supplementary table 2. Differentially expressed probes in the sensitive xenograft only
ILMN_Gene Source_Reference_ID
Definition
log2FC 
HPBx/HPXC
log2FC 
TSx/TSxCtrl
log2FC 
MPAx/MPAxCtrl ISRE STAT1
AIF1 NM_001623.3 allograft inflammatory factor 1 0.841 -0.044 -0.066
ATOH8 NM_032827.3 atonal homolog 8 (Drosophila) 0.734 -0.227 0.039
BEST4 NM_153274.1 vitelliform macular dystrophy 2-like 2 -0.829 -0.139 -0.043
BNIP3 NM_004052.2 BCL2/adenovirus E1B 19kDa interacting protein 3, nuclear gene encoding mitochondrial 
protein
-0.824 -0.175 0.112
CA9 NM_001216.1 carbonic anhydrase IX -1.073 0.099 0.028
CBLN4 NM_080617.4 cerebellin 4 precursor -1.446 0.075 -0.015
CCK NM_000729.3 cholecystokinin 1.644 0.021 0.315
CFH NM_001014975.1 complement factor H 1.242 0.257 -0.334 X
CHRD NM_177978.1 chordin -0.714 0.055 -0.105
CHRDL2 NM_015424.3 chordin-like 2 1.201 -0.103 0.391
COL10A1 NM_000493.2 collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia) -1.072 -0.084 0.2
COL2A1 NM_001844.3
collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital)
-1.097 -0.06 -0.27
COL9A1 NM_001851.3 collagen, type IX, alpha 1 -1.423 0.072 -0.185
CORT NM_001302.3 cortistatin 0.719 0.005 -0.11
CRYBA2 NM_057093.1 crystallin, beta A2 0.951 -0.028 0.158
CRYGS NM_017541.2 crystallin, gamma S 1.14 -0.057 -0.398
CTSC NM_001814.2 cathepsin C 0.806 0.116 0.192
DIO2 NM_001007023.1 deiodinase, iodothyronine, type II 1.181 -0.19 0.007
DKK1 NM_012242.2 dickkopf homolog 1 (Xenopus laevis) -0.674 -0.095 0.262
EDNRA NM_001957.1 endothelin receptor type A 0.586 -0.127 -0.119
EFNA1 NM_004428.2 ephrin-A1 -0.7 0.098 0.133
ENO2 NM_001975.2 enolase 2 (gamma, neuronal) -0.908 -0.053 0.53
FGFBP2 NM_031950.2 fibroblast growth factor binding protein 2 -0.975 -0.105 -0.004
FGFR1 NM_023110.1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) 0.637 -0.131 -0.328
GAS2L2 NM_139285.1 growth arrest-specific 2 like 2 -0.594 0.056 0.105
GPC1 NM_002081.1 glypican 1 -0.882 -0.142 0.301
GRIN2C NM_000835.3 glutamate receptor, ionotropic, N-methyl D-aspartate 2C -0.693 0.176 0.01
HS.131773 Hs.131773
AGENCOURT_6563847 NIH_MGC_119 cDNA clone IMAGE:5744832 5, mRNA sequence
0.656 0.015 0.012
HS.436379 Hs.436379 full-length cDNA clone CS0DM002YA18 of Fetal liver of (human) -0.637 0.019 0.098
HS.453381 Hs.453381 in27e08.x1 Human Fetal Pancreas 1B cDNA clone IMAGE: 3, mRNA sequence 0.762 -0.368 0.108
HS.573729 Hs.573729 UI-E-EO1-ajc-m-13-0-UI.s1 UI-E-EO1 cDNA clone UI-E-EO1-ajc-m-13-0-UI 3, mRNA 
sequence
0.728 0.065 -0.406
IBSP NM_004967.2 integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) -0.821 0.149 0.018
IL1R2 NM_173343.1 interleukin 1 receptor, type II 0.691 -0.104 0.003
ISYNA1 NM_016368.3 inositol-3-phosphate synthase 1 -0.722 -0.002 0.055
ITLN2 NM_080878.2 intelectin 2 -0.855 -0.043 0.126
KCTD5 NM_018992.1 potassium channel tetramerisation domain containing 5 -0.704 0.193 0.006
KRT85 NM_002283.2 keratin, hair, basic, 5 1.928 -0.001 0.213
LGALS7 NM_002307.1 lectin, galactoside-binding, soluble, 7, galectine 7 -0.785 -0.083 0.167
LGALS9 NM_009587.1 lectin, galactoside-binding, soluble, 9 (galectin 9) 1.26 0.318 0.433
LGALS9C XM_934665.1 lectin, galactoside-binding, soluble, 9C 1.197 0.571 0.228
LOC728910 XM_927748.1 PREDICTED: similar to Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1) -0.848 0.044 0.051
MAGEB2 NM_002364.3 melanoma antigen family B, 2 0.758 -0.044 -0.005
MATN4 NM_003833.2 matrilin 4 -0.933 -0.006 -0.033
MATN4 NM_030590.1 matrilin 4 -1.121 0.083 0.066
MFI2 NM_033316.2 antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 -1.644 0.026 0.116
MMP3 NM_002422.3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) -1.264 -0.092 0.16
MOXD1 NM_015529.1 monooxygenase, DBH-like 1 -0.787 -0.152 0.178
NDUFA4L2 NM_020142.3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 -0.725 0.23 0.542
NELF NM_015537.3 nasal embryonic LHRH factor -1.047 0.232 0.11
OLFML2B NM_015441.1 olfactomedin-like 2B 0.764 -0.032 -0.178
OMD NM_005014.1 osteomodulin -1.155 -0.24 -0.124
PLCD1 NM_006225.1 phospholipase C, delta 1 -0.607 0.068 0.114
PPP1R3C NM_005398.3 protein phosphatase 1, regulatory (inhibitor) subunit 3C -0.955 -0.082 0.232
PRSS35 NM_153362.1 protease, serine, 35 -1.045 0.071 -0.099
ROPN1 NM_017578.2 ropporin, rhophilin associated protein 1B -1.065 -0.042 -0.098
ROPN1B NM_001012337.1 ropporin, rhophilin associated protein 1B -0.651 0.016 0.001
ROPN1B XM_940725.1 PREDICTED: ropporin, rhophilin associated protein 1B, transcript variant 2 -1.172 -0.104 -0.081
S100P NM_005980.2 S100 calcium binding protein P -0.775 0.042 0.019
SCGB3A2 NM_054023.2 secretoglobin, family 3A, member 2 -0.842 0.051 -0.044
SERPINA3 NM_001085.4 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 -0.859 -0.054 -0.001
SH3BP4 NM_014521.1 SH3-domain binding protein 4 0.831 -0.062 0.026
SLAMF9 NM_033438.1 SLAM family member 9 -0.969 -0.101 0.063
SLC36A2 NM_181776.1 solute carrier family 36 (proton/amino acid symporter), member 2 -0.606 0.143 0.002
SLC8A3 NM_183002.1 solute carrier family 8 (sodium/calcium exchanger), member 3 -0.782 0.259 0.084
SNCAIP NM_005460.2 synuclein, alpha interacting protein 1.023 -0.118 0.034
SORCS2 NM_020777.1 sortilin-related VPS10 domain containing receptor 2 -0.855 -0.075 -0.268
SOX8 NM_014587.2 SRY (sex determining region Y)-box 8 -1.069 0.106 0.227
SYK NM_003177.3 spleen tyrosine kinase -0.685 0.068 0.135
T1560 NM_199048.1 T1560 protein 1.552 0.065 -0.037
UGT2B7 NM_001074.1 UDP glucuronosyltransferase 2 family, polypeptide B7 -0.75 -0.121 -0.084
UNQ1940 NM_205855.1 HWKM1940 -0.6 0.083 0.008
UNQ830 NM_206895.1 ASCL830 -0.992 0.172 0.005
Supplementary Table 3. Differentially expressed probes in two resistent xenografts
ILMN_Gene Source_Reference_ID
Definition
log2FC 
HPBx/HPXCtrl
log2FC 
TSx/TSxCtrl
log2FC 
MPAx/MPAxCtrl ISRE STAT1
AGRN NM_198576.2 agrin 0.31 1.30 0.881
AIM2 NM_004833.1 absent in melanoma 2 0.17 1.61 1.738 X
ARHGDIB NM_001175.4 Rho GDP dissociation inhibitor (GDI) beta 0.06 -0.91 -0.668
CD97 NM_078481.2 CD97 molecule 0.02 0.70 1.003 X
ELLS1 NM_152793.1 hypothetical protein Ells1 -0.46 -1.16 -1.174
HIST2H2AC NM_003517.2 histone cluster 2, H2ac 0.02 0.73 0.608
HS.145414 Hs.145414 aq28b01.y5 Barstead prostate BPH HPLRB4 1 cDNA clone IMAGE:2032201 5, 
mRNA sequence 0.33 2.02 2.211
HS.540498 Hs.540498 UI-E-EJ0-ahs-h-11-0-UI.r1 UI-E-EJ0 cDNA clone UI-E-EJ0-ahs-h-11-0-UI 5, mRNA 
sequence -0.12 3.18 0.707
IL4I1 NM_152899.1 interleukin 4 induced 1 0.54 1.30 2.113
LOXL3 NM_032603.2 lysyl oxidase-like 3 -0.06 0.66 0.78
MLKL NM_152649.1 mixed lineage kinase domain-like 0.17 0.74 0.823
PABPC1 NM_002568.3 poly(A) binding protein, cytoplasmic 1 0.01 -0.75 -0.642 X
PDGFRA NM_006206.3 platelet-derived growth factor receptor, alpha polypeptide -0.02 -0.61 -1.102 X
PRRX2 NM_016307.3 paired related homeobox 2 -0.05 0.64 0.732
REC8L1 NM_005132.1 REC8-like 1 (yeast) 0.34 1.49 1.31
TNFRSF10D NM_003840.3 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated 
death domain -0.06 -0.85 -0.77 X
TNFSF7 NM_001252.2 tumor necrosis factor (ligand) superfamily, member 7 0.04 0.60 0.757
TXNDC12 NM_015913.2 thioredoxin domain containing 12 (endoplasmic reticulum) -0.42 -1.46 -1.615
ZC3HAV1 NM_024625.3 zinc finger CCCH-type, antiviral 1 0.39 1.80 1.092 X
Supplementary table 4 Metabolic pathways representing genes overrepresented among 
those with altered expression 
Term Gene Countb %c p-value 
    
A. Genes with similar IFN response in HPBx, TSx and MPAx    
Panther BP    
BP00148:Immunity and defense 19 25.7 9.1E-08 
BP00031:Nucleoside, nucleotide and nucleic acid metabolism 22 29.7 1.9E-03 
BP00156:Interferon-mediated immunity 3 4.1 7.7E-03 
BP00101:Sulfur metabolism 7 9.5 8.8E-03 
BP00104:G-protein mediated signalling 21 28.4 1.4E-02 
BP00049:mRNA polyadenylation 5 6.8 2.0E-02 
BP00150:MHCI-mediated immunity 22 29.7 2.2E-02 
BP00076:Electron transport 8 10.8 2.5E-02 
BP00024:Acyl-CoA metabolism 4 5.4 2.8E-02 
BP00071:Proteolysis 24 32.4 3.0E-02 
BP00060:Protein metabolism and modification 16 21.6 3.7E-02 
BP00065:Protein methylation 4 5.4 4.9E-02 
Panther MF    
MF00197:Miscellaneous function 13 17.6 3.5E-05 
MF00170:Ligase 10 13.5 6.9E-05 
MF00042:Nucleic acid binding 41 55.4 1.0E-04 
MF00007:Interferon receptor 4 5.4 1.2E-03 
MF00006:Interleukin receptor 8 10.8 1.8 E-03 
MF00141:Hydrolase 11 14.8 2.2 E-03 
MF00262:Non-motor actin binding protein 21 28.4 3.0 E-03 
MF00035:Other ion channel 7 9.5 4.0 E-03 
MF00051:Helicase 8 10.8 5.0 E-03 
MF00067:mRNA polyadenylation factor 6 8.1 6.2 E-03 
MF00234:Other cytokine 7 9.5 7.4 E-03 
MF00242:RNA helicase 12 16.2 8.8 E-03 
MF00275:Transcription cofactor 7 9.5 1.0 E-02 
MF00098:Large G-protein 8 10.8 1.3 E-02 
MF00146:Deacetylase 5 6.8 1.3 E-02 
MF00153:Protease 7 9.5 1.6 E-02 
MF00044:Nuclease 7 9.5 2.8 E-02 
MF00039:Other transcription factor 9 12.2 3.0 E-02 
KEGG Pathway    
hsa04612:Antigen processing and presentation 9 12.1 2.3E-09 
hsa04940:Type I diabetes mellitus 4 5.4 9.9E-04 
hsa04514:Cell adhesion molecules (CAMs) 4 5.4 2.5E-02 
hsa04650:Natural killer cell mediated cytotoxicity 4 5.4 2.6E-02 
    
B. Genes differentially expressed in HPBx only    
Panther BP    
BP00124:Cell adhesion 9 13.6 4.9E-04 
BP00193:Developmental processes 12 18.2 1.7E-02 
BP00108:Receptor protein tyrosine kinase signaling pathway 5 7.6 3.9E-02 
BP00289:Other metabolism 15 22.7 4.2E-02 
Panther MF    
MF00016:Signaling molecule 9 13.6 1.8E-03 
MF00174:Complement component 6 9.1 3.7E-03 
MF00179:Extracellular matrix structural protein 5 7.6 1.9E-02 
MF00262:Non-motor actin binding protein 17 25.8 2.1E-02 
MF00137:Glycosyltransferase 9 13.6 2.3E-02 
MF00015:Other receptor 6 9.1 2.9E-02 
MF00250:Serine protease inhibitor 11 16.7 4.7E-02 
KEGG pathway    
hsa04020:Calcium signaling pathway 4 6.1 4.9E-02 
    
C. Genes with similar IFN response in TSx and MPAx    
Panther BP    
BP00196:Oogenesis 3 17.7 4.8E-02 
Panther MF    
MF00001:Receptor 5 29.4 2.4E-02 
KEGG pathway    
MF00001:Receptor 5 29.4 2.4E-02 
Supplementary table 4 Metabolic pathways representing genes overrepresented among 
those with altered expression 
aBased on lists of probes with significantly changed expression following IFN treatment 
identified by Limma analysis with restriction p <0.01. 
bTo avoid over-counting duplicated genes, the probe lists are converted to corresponding 
DAVID gene IDs by which all redundancy in original IDs are removed  
cThe gene-enrichment of functional categories and pathways was measured by determining 
the number of genes belonging to the functional group in the list, weighted against the total 
number of analyzed genes on arrays using Fisher Exact statistical test with restriction p <0.05. 
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